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Abstract 
 
ESAC, the EURL ECVAM Scientific Advisory Committee, advises EURL ECVAM on scientific 
issues. Its main role is to conduct independent peer review of validation studies of 
alternative test methods and to assess their scientific validity for a given purpose. The 
committee reviews the appropriateness of study design and management, the quality of 
results obtained and the plausibility of the conclusions drawn. ESAC peer reviews are 
formally initiated with a EURL ECVAM Request for ESAC Advice, which provides the 
necessary background for the peer-review and establishes its objectives, timelines and 
the questions to be addressed. The peer review is normally prepared by specialised ESAC 
Working Groups. These are typically composed of ESAC members and other external 
experts relevant to the test method under review. These experts may be nominated by 
ESAC, EURL ECVAM and partner organisations within the International Cooperation on 
Alternative Test Methods (ICATM). ESAC ultimately decides on the composition of these 
Working Groups. ESAC's advice to EURL ECVAM is formally provided as 'ESAC Opinions' 
and 'Working Group Reports' at the end of the peer review. ESAC may also issue 
Opinions on other scientific issues of relevance to the work and mission of EURL ECVAM 
but not directly related to a specific alternative test method.   
The ESAC Opinion expressed in this report relates to the peer-review of the validation 
study of the epiCS® Skin Irritation Test (SIT) based on the EURL ECVAM/OECD 
Performance Standards for in vitro skin irritation testing using Reconstructed human 
Epidermis (RhE). 
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Ispra, 24 June 2016 
ESAC Opinion 
 
In 2014, the EURL ECVAM Scientific Advisory Committee (ESAC) (Annex 1) was 
requested to peer review and offer an opinion as to whether the performance of the 
epiCS® RhE in vitro Skin Irritation Test (SIT) satisfies the relevant Performance 
Standards with a view to consideration of its use for routine dermal irritation testing 
hazard classification for regulatory purposes. Two ESAC Rapporteurs were appointed by 
ESAC at its 39th meeting to conduct a detailed scientific peer review of the test method 
and facilitate the ESAC Opinion requested by EURL ECVAM. The resulting ESAC Opinion 
(2014-01) of 17 November 2014 recommended that supplementary testing should be 
conducted at two laboratories to remove potential sources of bias from the chemical 
testing datasets made available to ESAC in 2014. 
The validation study was set up and managed by the test developer. The initial ring-trial 
was conducted in 2011. Further testing was performed in 2013 as the result of suspected 
proficiency problems at the testing laboratories. Additional testing was conducted and 
submitted to EURL ECVAM in 2015 following the recommendations of ESAC in its Opinion 
of November 2014. 
Following this new submission, the ESAC Rapporteurs (Annex 1) were asked by EURL 
ECVAM (Annex 2 - ESAC Request 2014-01, updated 31/03/2016) to take account of the 
additional data and analyses provided in a 2015 Report from the test developer in 
response to the ESAC Opinion. The ESAC Rapporteurs delivered a report dated 6 June 
2016 setting out their agreed position taking this additional information in to account 
(Annex 3). 
Having considered the 2015 test developer’s Report to EURL ECVAM, the ESAC 
Rapporteurs requested additional analysis in order to derive a dataset that they consider 
a more appropriate way to judge the performance of the test method. The results are 
shown in Table 1 below, including Clopper-Pearson exact 95 %-Confidence Intervals 
calculated by ESAC. 
 
 
Specific Recommendations 
There were issues with the performance of test kits shipped trans-continentally during 
the first phase of this study. Although the manufacturer attempted to identify and 
remedy the causes, there may have been some similar problems in the later part of the 
study. The manufacturer should investigate this, establish whether this was the case for 
example by confirming whether the quality control test kit batch-release criterion (i.e., 
measure of barrier function by incubation with Triton X-100) was/is still met when the 
test kits were/are received or used by the laboratory, and if necessary remedy the 
causes of the problems. 
 
 
Readiness for Standardised/Regulatory Use - Recommendation: 
On the basis of the best, albeit still imperfect, dataset currently available, the test 
method satisfies all but one of the Performance Standards target values: the overall WLR 
value obtained in one laboratory was 89 %.This value is marginally below the 
Performance Standards target value of 90 %.  
Page | 3 
Nevertheless, the ESAC believes that the test method has the potential to meet the PS 
target values provided that the specific recommendations above are addressed.  
Subject to these provisions, the ESAC believes the test method is suitable for screening 
purposes, and merits consideration for regulatory use. 
Of note, the ESAC also makes general recommendations on Performance Standards in a 
separate Opinion (ESAC, 2016), which are relevant to the current OECD Performance 
Standards on skin irritation (OECD Series on Testing and Assessment No. 220; OECD, 
2015). 
 
 
Table 1:  Re-calculated FINAL Results 
Validation Study Results based on Rapporteurs’ calculations 
PS Criteria Met 
Yes/No 
Lab. #1 – ACS 
Sensitivity 100 % (66–100 %)   
Specificity 80 % (44–97 %)   
Accuracy 89 % (67–99 %)   
  
Lab. #2 – HCCR 
Sensitivity   90 % (56–100 %)   
Specificity 80 % (44–97 %)   
Accuracy 85 % (62–97 %)   
  
Lab. #3 – IIVS 
Sensitivity 75 % (35–97 %)   
Specificity 80 % (44–97 %)   
Accuracy 78 % (52–94 %)   
  
For all three laboratories 
Sensitivity 89 % (71–98 %) Yes (PS ≥ 80 %) 
Specificity 80 % (61–92 %) Yes (PS ≥ 70 %) 
Accuracy 84 % (72–93 %) Yes (PS ≥ 75 %) 
WLR Lab. #1 – ACS   95 % (74–100 %) Yes (PS ≥ 90 %) 
WLR Lab. #2 – HCCR 100 % (83–100 %) Yes (PS ≥ 90 %) 
WLR Lab. #3 – IIVS 89 % (65–99 %) No (PS ≥ 90 %) 
BLR 
  
88 % (64–99 %) Yes (PS ≥ 80 %) 
% of complete run seq. in Lab. #1 – ACS   95 % (75–100 %) Yes (PS ≥ 85 %) 
% of complete run seq. in Lab. #2 – HCCR 100 % (83–100 %) Yes (PS ≥ 85 %) 
% of complete run seq. in Lab. #3 – IIVS 90 % (68–99 %) Yes (PS ≥ 85 %) 
% of complete run seq. over the three labs 95 % (86–99 %) Yes (PS ≥ 90 %) 
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1. TYPE OF REQUEST 
Request Type Identify request ("YES") 
R1 ESAC Peer Review  
of a Prevalidation Study or Validation Study 
YES, external validation study (i.e. not coordinated 
by EURL ECVAM) 
If R1)applies please specify further: 
►Prevalidation Study NO 
►Prospective Validation Study NO 
►Retrospective Validation Study NO 
►Validation Study based on Performance 
Standards 
YES 
The validation study is based on the Performance 
Standards (PS) for in vitro Skin Irritation testing using 
Reconstructed human Epidermis (RhE). The PS are 
outlined in the EURL ECVAM Performance Standards 
(EURL ECVAM 2009) and in the OECD Series on Testing 
and Assessment no. 220 (OECD 2015a). The first 
version of the OECD PS was included as an Annex in 
Test Guideline 439, which was first adopted in 2010 
(OECD 2010). The validation study was performed by 
the test method developer. 
R2 Scientific Advice on a test method submitted to 
EURL ECVAM for validation  
(e.g. the test method's biological relevance etc.) 
NO 
R3 Other Scientific Advice  
(e.g. on test methods, their use; on technical issues such as cell 
culturing, stem cells, definition of performance standards etc.) 
NO 
 
 
2. TITLE OF STUDY OR PROJECT FOR WHICH SCIENTIFIC ADVICE OF THE 
ESAC IS REQUESTED 
epiCS® Skin Irritation Study 
 
 
3. BRIEF DESCRIPTION OF THE STUDY OR PROJECT 
Important note: 
During the study phase the test submitter changed the name of the test method from EST1000 SIT to epiCS® SIT 
(SIT=Skin Irritation Test). The submitter has assured EURL ECVAM that the name change constitutes solely a 
change of trade name and that the test system (RhE) and associated SOP (way of conducting the test) have 
remained identical, i.e. not undergone any modification. 
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Summary 
The epiCS® (formerly known as EST1000) is a 3-dimensional Reconstructed human Epidermis (RhE) 
model consisting of normal primary human epidermal keratinocytes from one donor. The production 
process using defined media conditions leads to the differentiation of the cells and the formation of a 
multilayered epidermis. It consists of basal, spinous and granular layers and a multilayered stratum 
corneum highly comparable to native human skin. The epiCS® model was already validated for skin 
corrosion testing by EURL ECVAM in 2009 (ESAC 2009) and is accepted by the OECD for the 
classification of chemicals causing skin corrosion (OECD TG 431) (OECD 2015c). The current ESAC 
request concerns the scientific review of a submission of a validation study that was performed on 
the basis of Performance Standards (PS) for in vitro skin irritation testing using RhE. The relevant PS 
have been defined by EURL ECVAM (2009). They were also published in the OECD Series on Testing 
and Assessment No. 220 in 2015 (OECD 2015a), which accompany OECD TG 439 (OECD 2015b); the 
first version of the OECD PS was included as an Annex in Test Guideline 439, which was first adopted 
in 2010 (OECD 2010). 
The PS-based validation study to be reviewed was conducted by the test method developer 
(CellSystems, Germany) in between 2011 and 2015 (see below, 'History of submissions") and the final 
study and associated data were submitted to EURL ECVAM in Q4 2015. Like previously validated in 
vitro RhE-based skin irritation methods, the epiCS® Skin Irritation Test (SIT) is proposed to be capable 
of discriminating between not-classified (GHS No Category) and classified (GHS Categories 1 or 2) 
chemicals. It is not able to distinguish between irritant (GHS Category 2) and corrosive (GHS Category 
1) chemicals nor does it generate data on the optional GHS Category 3 ('mild irritants'). As GHS 
Category 3 is not implemented in the EU and other global regions, the method may serve in these 
regions as a full replacement to the skin irritation part of the traditional rabbit Draize skin test (OECD 
TG 404) (OECD 2015d), thus reducing the use of laboratory animals. 
The epiCS® SIT was first submitted to EURL ECVAM in 2009/2010 for an assessment of its compliance 
with the Essential Test Method components of the PS for RhE-based in vitro skin irritation test 
methods (EURL ECVAM 2009; OECD 2010; OECD 2015a). EURL ECVAM and ESAC confirmed that the 
epiCS® SIT qualified for a PS-based ("catch-up") validation study. The experimental ring trials 
(submitted in 2011 and, after retesting, in 2013 and 2015) had then the objective of assessing 
whether the epiCS® SIT meets the performance criteria in terms of reproducibility within and 
between laboratories and in terms of predictive capacity (sensitivity, specificity and accuracy of 
predictions). 
 
History of submissions 
a) In 2009, CellSystems submitted the EURL ECVAM Test Method "Proposal Evaluation Form", 
providing a short outline and description of the EST-1000 SIT test method. The proposal Evaluation 
Form served, at the time, as a presubmission step at EURL ECVAM. Having evaluated the proposed 
EST-1000 method, EURL ECVAM informed the submitter that the test method may qualify for a 
Performance-Standards based validation study depending however on a complete evaluation & 
conclusion of sufficient method similarity between the EST-1000 assay and the validated reference 
methods. The submitter was invited to submit a more comprehensive test method description in the 
EURL ECVAM "Test Submission Template" providing also historical data on test method development, 
batch stability, etc. 
b) In 2010 a detailed test method description was submitted in agreement with the provisions of 
EURL ECVAM's PS on skin irritation testing. This test method description addressed the essential test 
method components outlined in the EURL ECVAM Performance Standards (PS) for in vitro skin 
irritation test methods based on Reconstructed human Epidermis (RhE) (EURL ECVAM 2009)1. 
                                                 
1
 An abridged version of these PS is reproduced as Annex 2 of OECD TG 439. The PS of TG439 are identical to those of ECVAM but do not 
provide some of the detailed guidance contained in the ECVAM PS. 
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According to EURL ECVAM's approach for the validation of putative similar methods, confirmation of 
sufficient similarity (based on analysis of the essential test method components) of a putative similar 
method (='me-too method') with respect to the validated reference method(s), is a prerequisite for 
entering EURL ECVAM validation based on PS (="catch-up validation"). The assessment performed by 
EURL ECVAM in 2009 indicated full compliance with these criteria and ESAC (in Q1 2011) agreed with 
this assessment, confirming sufficient similarity to validate the test method using the Reference 
Chemicals and Target Reproducibility and Accuracy Values defined in the Performance Standards 
(EURL ECVAM 2009; OECD 2010; OECD 2015a). The TST also contained the current SOP and in-house 
testing data form the test method developer (optimisation & testing) providing preliminary 
information on the predictive capacity and reproducibility of the EST-1000 method. EURL ECVAM 
informed the submitter that the test method would qualify for PS-based validation and invited the 
submitter to submit a revised TST, once the PS-based ring trial employing three laboratories had been 
completed. 
c) In 2011, the Test Submitter completed a PS-based validation study based on a ring trial with three 
laboratories and submitted the documents to EURL ECVAM for assessment. The PS-based study 
addressed modules 1 to 6 (EURL ECVAM's modular approach). On the basis of the submitted results, 
EURL ECVAM concluded that the test method was not ready to progress to ESAC peer review as the 
target values for Within Laboratory Reproducibility (as defined in the PS) had not been met by any of 
the three participating laboratories: the concordance values observed were 74%, 84% and 84% 
(target value in PS is 90%). In addition, the Between Laboratory Reproducibility was slightly below 
the target value defined in the PS (78% compared to 80%, respectively). In contrast the predictive 
capacity target value was met (overall accuracy of 85%; PS stipulate accuracy ≥ 75%), and thus 
exceeded the performance of the validated reference method (VRM) (80 %).  
In ensuing communications EURL ECVAM and the submitter agreed that the test method appeared 
capable of discriminating not-classified from classified (irritants/corrosives) chemicals (predictive 
capacity met) but that there were issues with the reproducibility of the method (WLR and BLR) which 
might be due to inter alia transfer problems (e.g. shipment, lack of training) or intrinsic batch 
variability. 
Since the predictive capacity target value was met and since the BLR was very close to the threshold 
(2% difference), it was agreed that batch variability was rather unlikely (in this case PC and BLR would 
be expected to be affected to the same extent as WLR, which was not the case) and that probably 
issues of protocol transfer / training had caused the comparably low WLR values (especially in the 
naïve laboratory (ACS)), i.e. that insufficient attention had been given to ensure transferability of the 
method, in particular to the naïve laboratory. This assumption was further supported by the fact that 
no transfer phase had been conducted before the ring trial. Since the test developer assumed that 
both IIVS and Harlan were experienced users of RhE test methods, proficiency testing only with the 
negative and positive control had been conducted. As a consequence also the naïve laboratory (ACS) 
had not received transfer training and had not checked with chemicals other than positive and 
negative controls proficiency of conducting the method. It is therefore plausible that transfer issues 
had caused reproducibility problems. A small scale transfer phase (e.g. using the controls and a few 
test chemicals (e.g. n=4) or using the proficiency chemicals2 (TG 439) could have served to ensure 
successful transfer, or indicated already at this step issues. 
Therefore, EURL ECVAM recommended the following re-testing strategy: As the greatest variability 
had been observed at the naive laboratory, all 20 reference chemicals should be retested in three 
runs. The two other laboratories should at least retest the six reference chemicals that had given 
discordant results in three runs. Additionally, one of these labs had to re-test the chemical that 
                                                 
2
 Proficiency chemicals are used to ensure that a laboratory that is implementing a test method is indeed proficient in conducting the 
method. In any end user laboratory (e.g. CROs) proficiency should be assessed before routine testing commences and proficiency should 
moreover be assessed at regular intervals and whenever there are changes to laboratory personnel, equipment or testing conditions (e.g. 
new air condition, air flow etc.). 
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created an incomplete run sequence (1-decanol) in three runs. The data obtained after this retesting 
could then be compiled with the original data to arrive at a complete data matrix. It was 
communicated to the Submitter that this approach was only a recommendation and that the 
responsibility for choosing the appropriate approach to validate the test method was with the 
Submitter. 
d) In November 2013 a revised full dossier was submitted to EURL ECVAM containing a data matrix 
composed as recommended by EURL ECVAM (described above). Briefly, the results obtained were:  
 Occurrence of non-qualified tests/runs: A run is composed of the testing of one or several 
test chemicals in triplicate (tests) plus the testing of positive and negative controls. If the 
positive or negative controls are outside of the accepted ranges (ViabilityPC ≤ 20%; 1.0 ≤ 
ODNC ≤ 2.8) the run is considered not qualified and, consequently, all tests included within 
that run are also considered not qualified. The mean of triplicate values of each test is also 
calculated and if the SD > 18 %, the test is considered not qualified. Twenty out of the 1983 
tests conducted (10 %) were non-qualified (see statistical report, table on page 14). In 
comparison to the original study of 2011 (18.4 % non-qualified runs), the occurrence of non-
qualified tests appeared to decrease. The study acceptance criteria as stipulated in the PS 
(Section 3.3.1, paragraph 21) were met. 
 Complete run sequences: two of the three laboratories had complete run sequences for all 
20 chemicals following re-testing (100 %). The naïve laboratory (ACS) had complete run 
sequences for 19 out of 20 chemicals (95 %), thus meeting the acceptance criterion of ≥ 85 %. 
An incomplete run sequence was obtained for 1-methyl-3-phenylpiperazine since, in contrast 
to the last study (in 2009), ACS was unable to generate three qualified runs after a maximum 
of 5 independent runs (up to two re-tests). BLR could therefore be assessed only on the basis 
of 19 chemicals (PS outline that BLR should only be conducted for chemicals with valid run 
sequences in all laboratories). In total, 98.3 % of the run sequences were complete, thus 
meeting the acceptance criterion of ≥ 90 %. 
 Within-laboratory reproducibility (WLR): 95 % in ACS, 100 % in HCCR and 95% in IIVS (based 
on concordance of predictions of runs) 
 Between-laboratory reproducibility (BLR): 19 of the 20 chemicals were predicted 
concordantly by the three laboratories (95% concordance). For one chemical valid predictions 
were available only in 2 of 3 labs. This substance, in agreement with the PS, was not 
considered for BLR calculation. Of the 19 concordant predictions 17 were correct with respect 
to the in vivo reference data, while 2 where FPs. 
 False negative results were obtained for 1-methyl-3-phenylpiperazine at HCCR only, thus 
meeting the acceptance criteria for false negative results described in the PS. ACS produce 1 
qualified true positive result and 3 non-qualified false negative results for 1-methyl-3-phenyl-
1-piperazine, with the mean of the four runs also being false negative.  
 False positive results were obtained for allyl-phenoxy-acetate and cinnamaldehyde in all 
participating laboratories. 
 The sensitivity of ca 97 % (100 % at ACS and IIVS; 90 % at HCCR) was above the sensitivity of 
the VRM (ca 86 %) and thus met the acceptance criterion of ≥ 80 %. 
 The specificity of 80 % (80 % in all participating laboratories) was above the VRM (ca 77 %) 
and thus met the acceptance criterion of ≥ 70 %. 
 The overall accuracy of ca 88 % (89.5 % at ACS, 85 % at HCCR, 90 % at IIVS) was above the 
VRM (ca 80 %) and thus met the acceptance criterion of ≥ 75 %. 
                                                 
3
 This is the number of tests conducted per chemical during the study. The maximally possible number of tests is 5 per chemical (3 tests plus 
2 retests if required). Therefore, the maximal number of tests per study is 5 x 20 (reference chemicals) x 3 Laboratories = 300 tests. 
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 Some minor deviations from PS were observed concerning the time points & batches used for 
generating the data on reference chemicals. 
e) In October 2014, at its 40th plenary meeting, the ESAC expressed concerns on the way the second 
validation study of 2013 had been conducted. In particular, the ESAC questioned the appropriateness 
of the study design. These concerns were related to partial re-testing, in 2013, of the reference 
chemicals in two out of three laboratories (HCCR and IIVS), while the leading laboratory (ACS) re-
tested the entire set of 20 reference chemicals. At HCCR and IIVS, only 7 and 6 of the reference 
chemicals, respectively, had been re-tested in 2013. Hence, for these two laboratories, the data 
generated in 2011 and 2013 were grouped across the 20 chemicals. The ESAC deemed that grouping 
data introduced a bias in the data set generated from these two laboratories, since only non-
concordant data points had been re-tested. The ESAC therefore recommended that the remaining 13 
and 14 chemicals be re-tested respectively by HCCR and IIVS in order to complete the 2013 validation 
study and obtain an unbiased complete dataset. These remaining chemicals were re-tested in 2015.  
f) In October 2015, Cell Systems submitted to EURL ECVAM a full validation study complying with 
ESAC’s recommendations, i.e. containing new data for the 13 and 14 chemicals that had not been re-
tested respectively by HCCR and IIVS in the validation trial conducted in 2013. These data were 
submitted to EURL ECVAM together with a report that the submitter prepared on this re-testing.  
Different phases of the PS-based validation of the epiCS® SIT 
ACS HCCR IIVS 
2011 
20 chemicals 20 chemicals 20 chemicals 
ACS HCCR IIVS 
2013 + 2015 
2013 2013 2013 
20 chemicals re-tested 
7 chemicals re-tested 6 chemicals re-tested 
2015 2015 
 13 chemicals re-tested  14 chemicals re-tested 
 
Briefly, the results obtained with the pooled dataset from the studies of 2013 and 2015 are: 
 Occurrence of non-qualified tests/runs: A run is composed of the testing of one or several 
test chemicals in triplicate (tests) plus the testing of positive and negative controls. If the 
positive or negative controls are outside of the accepted ranges (ViabilityPC ≤ 20%; 1.0 ≤ ODNC 
≤ 2.8) the run is considered not qualified and, consequently, all tests included within that run 
are also considered not qualified. The mean of triplicate values of each test is also calculated 
and if the SD > 18 %, the test is considered not qualified. Thirty four out of the 212 tests 
conducted (16 %) were non-qualified. Of these 34 non-qualified tests, 16 occurred due to 
failure of the positive control rather than SD > 18 %. The occurrence of non-qualified tests is 
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similar to what was observed in the original study of 2011 (18 % non-qualified tests). The 
study acceptance criteria as stipulated in the PS (Section 3.3.1, paragraph 21) were met. 
 Complete run sequences: two of the three laboratories have complete run sequences for all 
20 chemicals following re-testing (100 %). The naïve laboratory (ACS) has complete run 
sequences for 19 out of 20 chemicals (95 %), thus meeting the acceptance criterion of ≥ 85 %. 
An incomplete run sequence was obtained for 1-methyl-3-phenyl-1-piperazine since ACS was 
unable to generate three qualified runs after a maximum of 5 independent runs (up to two 
re-tests). In total, 98.3 % of the run sequences are complete, thus meeting the acceptance 
criterion of ≥ 90 %. 
 The WLR of 94.7 % at ACS, 100 % at HCCR and 90 % at IIVS meets the acceptance criterion of 
≥ 90 %. 
 The BLR of 84.2 % meets the acceptance criterion of ≥ 80 %. Since the reference chemical 1-
methyl-3-phenyl-1-piperazine did not have complete run sequences in all laboratories, it was 
not considered for the calculation of BLR, according to the provisions of the PS (OECD 2015a). 
It should however be noted that a qualified false negative result and a qualified true positive 
result were obtained for this chemical at HCCR and IIVS, respectively, and therefore, the 
chemical did not show reproducible results between laboratories independently of the 
results obtained by ACS (where an incomplete run sequence was obtained). If this chemical 
was considered in the calculation of BLR, the value obtained would be 80 %. 
 The sensitivity of 86.2 % (100 % at ACS, 90 % at HCCR, 70 % at IIVS) meets the acceptance 
criterion of ≥ 80 %. 
 False negative results (based on the mean viability of the three qualified runs) were obtained 
for 1-methyl-3-phenyl-1-piperazine at HCCR, and for 1-bromohexane, 1-decanol and di-n-
propyl disulphide at IIVS, thus meeting the acceptance criteria for false negative results 
described in the PS. ACS produce 1 qualified true positive result and 3 non-qualified false 
negative results for 1-methyl-3-phenyl-1-piperazine, with the mean of the four runs also 
being false negative.  
 The specificity of 80 % (80 % in all participating laboratories) meets the acceptance criterion 
of ≥ 70 %. 
 False positive results (based on the mean viability of the three qualified runs) were obtained 
for allyl-phenoxy-acetate and cinnamaldehyde in all three participating laboratories. 
 The overall accuracy of 83.1 % (89.5 % at ACS, 85 % at HCCR, 75 % at IIVS) meets the 
acceptance criterion of ≥ 75 %. 
 A significant deviation from the PS was observed concerning the maximum number of re-
tests allowed. The PS specify that "to complement missing data, a maximum of two additional 
runs… ("re-testing")... may be conducted for each Reference Chemical in each laboratory. 
Non-qualified tests should be documented and reported" (OECD 2015a). This means that each 
laboratory should not test the same reference chemical more than five times. However, 1-
decanol and potassium hydroxide (5% aq) were tested 7 and 6 times, respectively, at IIVS 
because two extra runs not reported in the EURL ECVAM reporting template were not 
qualified: one, the second overall trial, due to failure of the positive control and the other, 
the fifth overall trial, due to contamination and failure of the positive control. It should also 
be noted that a true positive result (with SD < 18 %) was obtained for 1-decanol in trial 2 and, 
if this result was accepted, this chemical would have non-concordant results within IIVS, thus 
lowering the laboratory's WLR to 85 %, which is lower than the acceptance criterion of ≥ 90 
%. 
 
With these new data and information, the submitter is requesting that ESAC reconsiders/revises its 
opinion of 2014.  
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4. OBJECTIVES, QUESTIONS, TIMELINES 
4.1  OBJECTIVE 
Objective 
Why does EURL 
ECVAM require 
advice on the 
current issue? 
The opinion of ESAC should conclude on the quality of the submitted 
Performance Standards-based validation study on the epiCS® SIT, which 
addressed the reliability (transferability, within and between laboratory 
reproducibility) and the predictive capacity of the epiCS® SIT. The opinion should 
conclude on the equivalence of the performance of epiCS® SIT to that of the 
validated reference methods as outlined in the Performance Standards. Overall, 
the ESAC opinion, based on the review of the submitted study dossier, should 
conclude on the adequacy of the epiCS® SIT for routine dermal irritation testing 
for regulatory purposes. 
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4.2  QUESTION(S) TO BE ADDRESSED 
Questions 
What are the 
questions and 
issues that should 
be addressed in 
view of achieving 
the objective of 
the advice? 
UPDATED REQUEST 
(1) Background: 
In 2014, the ESAC was requested to review whether the validation study was 
conducted appropriately in view of the objective of the study. The study 
objective was to assess the following parameters in comparison to respective 
criteria outlined in the Performance Standards: 
(a) the reproducibility of the epiCS® SIT within laboratories (WLR) 
(b) its transferability to other laboratories 
(c) its reproducibility between laboratories (BLR) 
(d) its predictive capacity 
 
(2) Questions to ESAC (March 2016): 
The ESAC is now requested to reconsider its previous scientific review of the 
epiCS® SIT and to revise the ESAC Rapporteur Report and Opinion of November 
2014, if/where appropriate, on the basis of the new data and information 
submitted to EURL ECVAM in October 2015. In particular, the ESAC is requested 
to assess the new data and information against the criteria set out in the 
Performance Standards on in vitro skin irritation testing based on RhE and to 
conclude: 
(a) whether the re-testing performed in 2015 was adequately conducted, 
especially in light of the previous ESAC opinion 
(b) whether the final dataset including the data generated after the re-testing 
conducted in 2015 is complete and unbiased. This item also includes adequate 
reporting of the re-testing data (e.g., adequate reporting of non-qualified runs, 
controls and chemicals) 
(c) whether the number of re-tests/re-runs is acceptable 
(d) whether the reproducibility of the epiCS® SIT within each of the participating 
laboratories  (WLR) is acceptable 
(e) whether the reproducibility of the epiCS® SIT between laboratories (BLR) is 
acceptable 
(f) whether the predictive capacity of the epiCS® SIT is acceptable 
(g) whether the overall performance of the method is sufficient in view of its use 
for routine dermal irritation testing for regulatory purposes 
N.B. Similarity of the epiCS® had been confirmed previously and, therefore, the 
essential test method components relating to the test system do not need to be 
reviewed. 
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4.3  TIMELINES 
Timelines 
concerning this 
request 
When does EURL 
ECVAM require 
the advice? 
Timeline Indication 
Finalised ESAC Opinion required by: April 2014 
Updated opinion: June 2016 
Request to be presented to ESAC by 
written procedure (e.g. due to 
urgency) prior to the next ESAC 
YES 
Request to be presented to ESAC at 
ESAC plenary meeting 
ESAC Request discussed at ESAC39 
11/12 March 2014. 
Updated ESAC Request of March 
2016 shall not be discussed at an 
ESAC plenary meeting 
 
 
 
 
5.  EURL ECVAM PROPOSALS ON HOW TO ADDRESS THE REQUEST WITHIN 
ESAC 
5.1  EURL ECVAM PROPOSAL REGARDING REQUEST-RELATED STRUCTURES REQUIRED 
Specific 
structures 
required within 
ESAC to address 
the request 
Does the advice 
require an ESAC 
working group, an 
ESAC rapporteur 
etc.? 
Structure(s) required Required according to EURL ECVAM? 
(YES/NO) 
S1 ESAC Rapporteur YES 
S2 ESAC Working Group NO 
S3 Invited Experts NO 
Ad S3: If yes – list names and 
affiliations of suggested 
experts to be invited and 
specify whether these are 
member of the EEP 
Jon Richmond (ESAC member) – lead drafter 
Renate Krätke (ESAC member) 
If other than above (S1-S3):   
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5.2  DELIVERABLES AS PROPOSED BY EURL ECVAM 
Deliverables 
What deliverables 
(other than the 
ESAC opinion) are 
required for 
addressing the 
request? 
Title of deliverable other 
than ESAC opinion 
Required? (YES/NO) 
D1 ESAC Rapporteur Report 
and draft opinion  
YES (a revision of the report and opinion from 
2014) 
D2 ESAC Peer Review Report 
and draft opinion 
NO 
If other than above (D1-D2):  
 
 
6. LIST OF DOCUMENTS TO BE MADE AVAILABLE TO THE ESAC 
 
Count Description of 
document/document set 
Already 
available? 
(YES/NO) 
File name 
FOLDER: 1. DOCUMENT SET: Submission 2013 
1 Standard Operating Procedure for 
EPIDERMAL SKIN TEST 1000 (EST1000) SKIN 
IRRITATION TEST, version 1.0 of June 2011  
Yes 1a_INVITTOX_Protocol_EST1000_ 
SIT_SOP.pdf 
2 Standard Operating Procedure for epiCS® in 
vitro skin irritation, INVITTOX Protocol, 
version 4.0 of November 2012 
Yes 1b_INVITTOX_Protocol_epiCS_ 
SIT_SOP.pdf 
3 List of test chemicals Yes 2_EST1000_SIT_chemicals_set.xls 
4 Study Plan for the catch-up validation study 
on in vitro skin irritation using epidermal 
skin test 1000 (EST1000)- Version 3 for the 
initial study (2011) 
Yes 13a_EST1000_SIT_Study_plan_ 
initial.pdf 
5 Test Plan: Study on in vitro skin irritation 
using epiCS; additional testing, version 2.0 
(2013) 
Yes 13b_EST1000_SIT_Study_plan_ 
completed.pdf 
6 OECD Testguideline 439 "In Vitro Skin 
Irritation: Reconstructed Human Epidermis 
Test Method", version adopted 07/2010 
Yes 15_OECD_TG_439_2010.pdf 
7 List of 24 references Yes 16a_References_List_EST1000_SIT.pdf 
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8 Scientific publication: 
Hoffmann J, Heisler E, Karpinski S, Losse J, 
Thomas D, Siefken W, Ahr HJ, Vohr HW, 
Fuchs HW (2005). Epidermal-skin-test 1000 
(EST-1,000)--a new reconstructed epidermis 
for in vitro skin corrosivity testing. Toxicol 
In Vitro. Oct;19(7):925-9 
Yes 16b_Hoffmann_EST1000.pdf 
9 Statistical Report from BfR for the initial 
study: "Evaluation of the Catch-up 
Validation study of the Epidermal Skin Test 
1000 (EST1000) for in vitro skin irritation 
testing", version of 14 November 2011 
Yes 17a_Statistical_Report_EST1000_ 
initial.pdf 
10 Statistical Report from seh consulting for 
the completed study: "Evaluation of the 
Catch-up Validation study of epiCS® 
(formerly: Epidermal Skin Test 1000 
(EST1000)) for in vitro skin irritation 
testing", version of 5 September  2013 
Yes 17b_Statistical_Report_EST1000_ 
completed.pdf 
11 Lot Release Certificate Epidermal Skin Test 
1000 EST1000 as an example for QA 
Yes 17c_Lot_Release_Certificate.pdf 
12 Letter ECVAM-Test submitter of 
19.12.2012; on agreed retesting procedure  
Yes 17d_Submission of test method based 
on EST-1000-epiCS for skin irritation 
hazard identification.pdf 
13 ECVAM Test Submission Template (TST) for 
EST1000 SIT study / epiCS SIT study, 
(November 5, 2013) 
Yes ECVAM_test_submission_template_ 
epiCS_SIT_completed,05.11.2013.pdf 
FOLDER: 2. DOCUMENT SET: Submission 2011 
14 Standard Operating Procedure for 
EPIDERMAL SKIN TEST 1000 (EST1000) SKIN 
IRRITATION TEST, version 1.0 of June 2011 
Yes 1_INVITTOX_Protocol_EST1000_ 
SIT_SOP.DOC 
15 List of test chemicals Yes 2_EST1000_SIT_chemicals_set.xls 
16 Study Plan for the catch-up validation study 
on in vitro skin irritation using epidermal 
skin test 1000 (EST1000)- Version 3 for the 
initial study (2011) 
Yes 13_EST1000_SIT_Study_plan.doc 
17 OECD Test guideline 439 "In Vitro Skin 
Irritation: Reconstructed Human Epidermis 
Test Method", version adopted 07/2010 
Yes 15_OECD_TG_439_2010.pdf 
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18 Scientific publication: 
Hoffmann J, Heisler E, Karpinski S, Losse J, 
Thomas D, Siefken W, Ahr HJ, Vohr HW, 
Fuchs HW (2005). Epidermal-skin-test 1000 
(EST-1,000)--a new reconstructed epidermis 
for in vitro skin corrosivity testing. Toxicol 
In Vitro. Oct;19(7):925-9 
Yes 16_Hoffmann_EST1000.pdf 
19 List of 24 references Yes 16_References_List_EST1000_SIT.doc 
20 Lot Release Certificate Epidermal Skin Test 
1000 EST1000 as an example for QA 
Yes 17_Lot_Release_Certificate.pdf 
21 Statistical Report from BfR for the initial 
study: "Evaluation of the Catch-up 
Validation study of the Epidermal Skin Test 
1000 (EST1000) for in vitro skin irritation 
testing", version of 14 November 2011 
Yes 17_Statistical_Report.pdf 
22 Summary of EST1000 SIT validation study Yes 17_Summary_EST1000_SIT.docx 
23 ECVAM Test Submission Template (TST) for 
the EST1000 SIT study, (15 November 2011) 
Yes ECVAM_test_submission_template_ 
EST1000_SIT.doc 
FOLDER: 3. EURL ECVAM Performance Standards 
24 ECVAM Performance Standards for Skin 
Irritation Testing (updated) – 24.8.2009 
Yes ECVAM_PS_2009_updated.pdf 
FOLDER: 4. DOCUMENT SET: Submission 2015 
25 Excel file: trial 1 conducted in 2015 at HCCR Yes Harlan, trial 1, epiCS SIT method, final 
testing.xlsx 
26 Excel file: trial 2 conducted in 2015 at HCCR Yes Harlan, trial 2, epiCS SIT method, final 
testing.xlsx 
27 Excel file: trial 3 conducted in 2015 at HCCR Yes Harlan, trial 3, epiCS SIT method, final 
testing.xlsx 
28 Excel file: trial 4 conducted in 2015 at HCCR Yes Harlan, trial 4, epiCS SIT method, final 
testing.xlsx 
29 Excel file: trial 1 conducted in 2015 at IIVS Yes IIVS, trial 1, epiCS SIT method, final 
testing.xlsx 
30 Excel file: trial 2 conducted in 2015 at IIVS Yes IIVS, trial 2, epiCS SIT method, final 
testing.xlsx 
31 Excel file: trial 3 conducted in 2015 at IIVS Yes IIVS, trial 3, epiCS SIT method, final 
testing.xlsx 
32 Excel file: trial 4 conducted in 2015 at IIVS Yes IIVS, trial 4, epiCS SIT method, final 
testing.xlsx 
33 Excel file: trial 5 conducted in 2015 at IIVS Yes IIVS, trial 5, epiCS SIT method, final 
testing.xlsx 
34 Excel file: trial 6 conducted in 2015 at IIVS Yes IIVS, trial 6, epiCS SIT method, final 
testing.xlsx 
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35 Excel file: trial 7 conducted in 2015 at IIVS Yes IIVS, trial 7, epiCS SIT method, final 
testing.xlsx 
36 Excel file: report of the data by the 
submitter in the EURL ECVAM template 
Note: EURL ECVAM offered this template to the 
submitter in order to facilitate consistent 
reporting of the data. However, EURL ECVAM 
specified that the use of this template was NOT 
mandatory and declined any responsibility on its 
possible inappropriate use (see disclaimer) 
Yes epiCS SIT method, EURL ECVAM 
reporting sheet, final testing, 
27.10.2015.xlsx 
37 Submitter's report on the re-testing 
conducted in 2015  
Yes Report on epiCS SIT final testing, 
29.10.2015.pdf 
38 ESAC Opinion of November 2014 Yes Ares(2014)4229618_ESAC opinion.pdf 
39 EURL ECVAM Reply Letter to the Submitter 
of December 2014 
Yes Ares(2014)4229618_Reply letter 
16122014.pdf 
40 OECD Test Guideline 439 "In Vitro Skin 
Irritation: Reconstructed Human Epidermis 
Test Method", version adopted 07/2015 
Yes OECD TG439 2015.pdf 
41 OECD Series on Testing and Assessment No. 
220  "Performance Standards for the 
Assessment of Proposed Similar or 
Modified In Vitro Reconstructed Human 
Epidermis (RhE) Test Methods for Skin 
Irritation Testing as Described in TG 439", 
version adopted 07/2015 
Yes OECD STA220 2015.pdf 
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7. TERMS OF REFERENCE OF THE ESAC RAPPORTEURS 
7.1 ESTABLISHMENT OF THE ESAC RAPPORTEURS 
During its 38th meeting June 2013 the ESAC plenary unanimously decided to charge two ESAC 
members to act as rapporteurs to prepare a scientific review of a Performance Standards based 
study on the epiCS® RhE skin irritation test method. 
 
7.2 TITLE OF THE ESAC RAPPORTEURS 
epiCS Review 2014/2016  
 
7.3 MANDATE OF THE ESAC RAPPORTEURS 
The Rapporteurs are requested to reconsider the scientific review of the epiCS® SIT performed in 
2014 on the basis of the new data and information submitted to EURL ECVAM in October 2015. The 
Rapporteurs are requested to revise the ESAC Rapporteur Report and Opinion of November 2014, 
if/where appropriate, considering the performance of the epiCS® SIT in reference to the Performance 
Standards on in vitro skin irritation testing based on RhE. 
The review should focus on the appropriateness of design and conduct of the study in view of the 
study objective and should provide an appraisal to which extent the conclusions of the Validation 
Management Team (VMT) or the Submitter are substantiated by the information generated during 
the study and how the information generated relates to the scientific background available. 
 
7.4 DELIVERABLES OF THE ESAC RAPPORTEURS 
The ESAC WG is requested to deliver to the chair of the ESAC and the ESAC Coordinator a revised 
Rapporteur Report outlining its analyses and conclusions and a draft revised ESAC opinion. 
 
The conclusions drawn in the report should be based preferably on consensus. If no consensus can 
be achieved, the report should clearly outline the differences in the appraisals and provide 
appropriate scientific justifications. 
 
7.5 PROPOSED TIMELINES OF THE ESAC RAPPORTEURS 
Item Proposed date/time Action Deliverable 
1 March 2014 Teleconference Kick-off discussions 
2 Beginning of April 2014 Circulation of first version of draft 
report 
Done 
3 End of April 2014 Circulation of final rapporteur 
report. 
Done 
4 End of April 2016 Circulation of first revised versions 
of rapporteur report and opinion 
 
5 End of May 2016 Circulation of final revised 
versions of rapporteur report and 
opinion 
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7.6 QUESTIONS WHICH SHOULD BE ADDRESSED BY THE ESAC RAPPORTEURS 
The review should address the questions put forward to ESAC by EURL ECVAM (see section 4.2) and 
the information requirements of the ESAC Working Group Template, where applicable. The ESAC 
Coordinator(s) will provide guidance if needed. 
 
 
APPENDIX 1   REPORTING TEMPLATE 
The appended ESAC WG template suggests a structure that is in close agreement with the EURL 
ECVAM information requirements ("modules") for scientific review following validation and allows at 
the same time for the description of the analysis and conclusions concerning more specific questions.  
 
The template can be used for various types of validation studies (e.g. prospective full studies, 
retrospective studies, performance-based studies and prevalidation studies). Depending on the study 
type and the objective of the study, not all sections may be applicable.  
 
However, for reasons of consistency and to clearly identify which information requirements have not 
been sufficiently addressed by a specific study, this template is uniformly used for the evaluation of 
validation studies. 
 
The current template is 
 
TEMPLATE_ESAC-WG_REPORT-v6.doc 
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ESAC Rapporteurs 
 
Rapporteurs were appointed by the ESAC 39 meeting to facilitate the ESAC Opinion requested in the 
“ECVAM REQUEST FOR ESAC ADVICE on the validation study of the epiCS® test method based on the 
EURL ECVAM/OECD Performance Standards for in vitro skin irritation testing using Reconstructed 
human Epidermis (RhE)” dated 21 February 2014 (ESAC Request 2014-01).  
The Rapporteurs were tasked with conducting a detailed scientific peer review of an external 
Performance Standards-based “catch-up” validation study submitted by the test method developer 
based on the provisions of the relevant Performance Standards (PS) (EURL ECVAM Performance 
Standard 2009, and OECD TG439 2013) for in vitro skin irritation test methods using Reconstructed 
human Epidermis (RhE).  
The October 2014 Rapporteurs Report (V3) represented their consensus view on the information 
available at that time.   
The resulting ESAC Opinion (2014-1) of 17/11/2014 recommended that supplementary testing should 
be conducted at two laboratories to remove potential sources of bias from the chemical testing 
datasets. 
The Rapporteurs have now been asked (ESAC Request 2014-01, updated 31/03/20161) to take 
account of additional data and analysis provided in a 2015 Report from the test developer in 
response to the ESAC Opinion and subsequent correspondence. 
This document (V 4.0) sets out the Rapporteurs’ agreed position taking this additional information in 
to account. 
 
The ESAC Rapporteurs: 
 Dr. Jon Richmond 
 Dr. Renate  Krätke 
 
ESAC Coordination:  
 Dr. Claudius Griesinger (ESAC Coordinator; 2014) 
 Dr. Michael Schäffer (2014) 
 Dr. João Barroso (ESAC Coordinator; 2016) 
 
                                                 
1 The revised ESAC request references the Performance Standards set out in the 2015 OECD documents (the 
original ESAC requested made reference to the 2013 Edition). 
OECD (2015a). OECD Series on Testing and Assessment, No. 220: Performance Standards for the Assessment of 
Proposed Similar or Modified In Vitro Reconstructed Human Epidermis (RhE) Test Methods for Skin 
Irritation Testing as Described in TG 439. Organisation for Economic Cooperation and Development, Paris. 
OECD (2015b). OECD Guideline for the Testing of Chemicals, No. 439: In Vitro Skin Irritation: Reconstructed 
Human Epidermis Test Method. Organisation for Economic Cooperation and Development, Paris. 
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Abbreviations used in the document 
 BLR   Between-laboratory reproducibility 
 EURL ECVAM European Union Reference Laboratory for Alternatives to Animal 
Testing 
 ESAC   EURL ECVAM Scientific Advisory Committee 
 ESAC WG  ESAC Working Group 
 GLP   Good Laboratory Practice 
 OECD   Organisation for Economic Cooperation and Development 
 PC   Positive Control 
 PS   Performance Standards 
 RC   Reference Chemical 
 RhE   Reconstructed human Epidermis 
 SD   Standard deviation 
 SOP   Standard Operating Procedure (used here as equivalent to 'protocol') 
 TS   Test Submission 
 VMT   Validation Management Team 
 VRM   Validated Reference Methods 
 WLR   Within-laboratory reproducibility 
ESAC RAPPORTEURS REPORT  Page | 33 
EXECUTIVE SUMMARY 
In 2014 ESAC was requested to peer review and offer an opinion as to whether the performance of 
the epiCS® RhE in vitro skin irritation method satisfies the relevant Performance Standards with a 
view to consideration of its use for routine dermal irritation testing hazard classification for 
regulatory purposes. 
The validation study was set up and managed by the test developer. The initial ring-trial was 
conducted in 2011. Further testing was performed in 2013 as the result of suspected proficiency 
problems at the testing laboratories (see 1.3.2 and 8). Additional testing was conducted and reported 
in 2015 following a 2014 ESAC Recommendation raising concerns about possible sources of bias in 
the data-set made available to ESAC in 2014 (see 1.3.3 and 1.4 and 4.2).  
Having considered the 2015 test developer’s Report to EURL ECVAM, the ESAC Rapporteurs 
requested additional analysis in order to derive a dataset that they consider a more appropriate way 
to judge the true performance of the test method (see below and 10). The results which the ESAC 
Rapporteurs believe should be used to judge the performance of the test method are shown in table 
1 immediately below, including Clopper-Pearson exact 95 %-Confidence Intervals calculated by ESAC. 
 
TABLE 1:  ESAC Rapporteurs’ Re-calculated FINAL Results 
Validation Study Results based on Rapporteurs’ calculations 
PS Criteria Met 
Yes/No 
Lab. #1 – ACS 
Sensitivity 100 % (66–100 %)   
Specificity 80 % (44–97 %)   
Accuracy 89 % (67–99 %)   
  
Lab. #2 – HCCR 
Sensitivity   90 % (56–100 %)   
Specificity 80 % (44–97 %)   
Accuracy 85 % (62–97 %)   
  
Lab. #3 – IIVS 
Sensitivity 75 % (35–97 %)   
Specificity 80 % (44–97 %)   
Accuracy 78 % (52–94 %)   
  
For all three laboratories 
Sensitivity 89 % (71–98 %) Yes (PS ≥ 80 %) 
Specificity 80 % (61–92 %) Yes (PS ≥ 70 %) 
Accuracy 84 % (72–93 %) Yes (PS ≥ 75 %) 
WLR Lab. #1 – ACS   95 % (74–100 %) Yes (PS ≥ 90 %) 
WLR Lab. #2 – HCCR 100 % (83–100 %) Yes (PS ≥ 90 %) 
WLR Lab. #3 – IIVS 89 % (65–99 %) No (PS ≥ 90 %) 
BLR 
  
88 % (64–99 %) Yes (PS ≥ 80 %) 
% of complete run seq. in Lab. #1 – ACS   95 % (75–100 %) Yes (PS ≥ 85 %) 
% of complete run seq. in Lab. #2 – HCCR 100 % (83–100 %) Yes (PS ≥ 85 %) 
% of complete run seq. in Lab. #3 – IIVS 90 % (68–99 %) Yes (PS ≥ 85 %) 
% of complete run seq. over the three labs 95 % (86–99 %) Yes (PS ≥ 90 %) 
 
With the exception of the WLR in one laboratory (at 88.89%, marginally short of the PS required 
minimum value of ≥ 90%) all of the PS criteria are met. 
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Whilst one of the relevant Performance Standards makes provision for deviations from the 
acceptance criteria2 - the other does not. 
 
 
INTRODUCTION 
In 2014 ESAC was requested to evaluate a study plan and a composite data set (submitted by the test 
developer to ECVAM in 2013) selectively merging and substituting data from two phases of chemical 
testing: an initial 2011 study (TM2009-09), and a later testing phase generating supplementary test 
data on selected chemicals after additional training and proficiency testing measures were 
introduced at the participating laboratories (see 1.3.2 and 8). ESAC was specifically asked to review 
and offer an opinion as to whether the overall performance of the epiCS® in vitro skin irritation 
method satisfies the relevant Performance Standards in view of its potential use for routine dermal 
irritation testing hazard classification for regulatory purposes. 
The resulting ESAC Opinion (2014-01 (17/11/2014)) concluded on the basis of that hybrid data-set 
that the majority of the PS performance criteria had been met. However, there were concerns that 
the testing programme and hybrid data-set produced by selectively mixing test data from 2011 and 
2013 may have introduced an “optimism bias” making it impossible at that time to properly evaluate 
test method performance (see 1.3.3 and 1.4 and 4.2): the ESAC opinion therefore recommended 
further testing and analysis to address this concern.  
That resulted in a third round of testing which forms the basis of a Report from the test developer to 
EURL ECVAM in October 2015. ESAC has now been asked to advise on the performance of the test 
method taking account of data and analysis presented in the test developer’s Report to ECVAM of 
October 2015.  
 
 
BACKGROUND 
2009 
CellSystems submitted an ECVAM Test Method "Proposal Evaluation Form", providing a short outline 
and description of the EST-1000 SIT in vitro skin irritation test method. ECVAM informed the 
submitter that the test method may qualify for a Performance Standards-based validation study 
subject to a more complete evaluation confirming sufficient methodological similarity between the 
EST-1000 assay and the validated reference methods (VRMs). The submitter was invited to submit 
additional information.  
 
2010  
A more detailed test method description was submitted by the test developer in 2010 addressing the 
essential test method components outlined in the ECVAM PS for in vitro skin irritation test methods 
based on Reconstructed human Epidermis (RhE) test systems (ECVAM 2009). The assessment then 
performed by ECVAM indicated full compliance with these criteria and ESAC (in Q1 2011) agreed 
with this assessment. ECVAM informed the submitter that the test method would qualify for PS-
based validation and invited the submitter to submit a revised Test Submission (TS) once a PS-based 
ring trial employing three laboratories had been completed. 
 
                                                 
2
 For example, the 2009 ECVAM Performance Standard (page 5) states “...it is conceivable that deviations from 
these standards may be justified be scientific reasons...”. The OECD Performance Standard does not contain 
this provision. 
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2011 
In 2011 the test developer, having conducted a first PS-based validation study of the epiCS® test 
method (then known as EST-1000), submitted the findings to EURL ECVAM. While the performance 
indices derived from the study data met the target values relating to Predictive Capacity (Specificity, 
Sensitivity and Accuracy) as outlined in the PS, the trial data did not satisfy the criteria established in 
the PS for Reproducibility: within Laboratory Reproducibility (WLR) being 16% below the target value 
in the naïve laboratory, and 6% below the target value in the other two laboratories; and the 
Between Laboratory Reproducibility (BLR) being 2% below the target value.  
 
The 2011 ring-trial did not include a transfer, training and proficiency phase (see 1.3.2 and 8). It was 
considered that this omission may have contributed to the poor Reproducibility values reported in 
the 2011 submission. No ESAC opinion was sought at that time. 
The Rapporteurs note that during this phase of the validation study the nature of the plastic inserts 
which form part of the test kit were changed, but that this did not compromise test performance 
values. The Rapporteurs consider that the ability of the test method to withstand such a change in 
manufacturing process tends to confirm the robustness of the test method and its external validity. 
 
2013 
After remedial action by the manufacturer to improve the transport of the test kits to the 
laboratories, and to improve the technical proficiency and compliance of the laboratories in 
particular with respect to how to execute crucial SOP steps (relating to chemical storage, test 
material application and its removal, i.e. rinsing procedure), supplementary testing of the full set of 
RCs at the naïve laboratory, and re-testing of a subset of chemicals at the other laboratories was 
undertaken.  
The supplementary testing and analysis that under-pinned the 2013 submission can be summarised 
as follows: the naïve laboratory had the worst WLR performance and re-tested the original 20 
reference chemicals; the other two laboratories had also failed to meet the WLR acceptance criteria 
as outlined in the PS (which states 90% of the 20 chemicals to be concordantly predicted between 
runs) and re-tested only the six chemicals responsible for most of the Reproducibility errors 
observed, and a seventh chemical in one of the laboratories only because it generated invalid run 
sequences during the 2011 ring-trial. In the 2013 submission to EURL ECVAM revised WLR and BLR 
values had been calculated by substituting the new data from all three laboratories for the results 
obtained for the same chemicals in the same laboratories as reported in the 2011 submission to 
EURL ECVAM. It is on that basis revised Reproducibility and Accuracy figures were calculated and 
supplied to EURL ECVAM by the test developer in 2013.  
In their 2014 peer review the Rapporteurs were satisfied that the available data tended to confirm 
that the most plausible explanations for the poor Reproducibility in the 2011 ring trial were: 
(a) The poor proficiency, in particular but not exclusively, of the naïve laboratory. Moreover, on 
the basis of 2013 supplementary data, and additional analysis provided by the test method 
developer in a letter dated September 2014, this was also seen to have been an issue at the 
two non-naïve laboratories. Proficiency and compliance issues mainly concerned the 
washing/rinsing procedure, which, although described in the SOP, was not properly followed. 
(b) Problems with the shipment of the tissues in case of the US laboratory. 
(c) The fact that tissue kits that had been exposed to different chemicals had been placed next 
to each other during the post-incubation period. While this step follows the washing 
procedure intended to remove the test chemical, potential cross-contamination issues could 
not be ruled-out (see also section 16. Recommendations).  
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In evaluating the 2013 submission to EURL ECVAM, the Rapporteurs considered that elements of the 
supplementary testing and data analysis may have introduced sources of bias into the datasets 
submitted to EURL ECVAM in 2013 (as discussed in more detail below and summarised at 1.3.3 and 
1.4), and to have breached the PS requirements with respect to repeated testing. The Rapporteurs 
therefore viewed the 2013 submission as an adjunct explaining and supporting, rather than 
replacing, the 2011 submission.  
The Rapporteurs were therefore concerned that the reported Reproducibility and Accuracy of the 
epiCS® test method set out in the 2013 Test Submission may not be based on the most reliable 
dataset to use to interpret the findings of this study with respect to Reproducibility or Reliability. 
Specifically, the Rapporteurs concluded that there were two features of the 2013 study design and 
data analysis which represented potential sources of bias potentially over-estimating the 
performance of the test method. 
 First: the PS state that for validation studies, the Reference Chemicals (RCs) which are used 
for PS-based validation, should not be used for development and optimisation of the test 
method (EURL ECVAM, 2009; OECD, 2015a). However, to develop and optimise the epiCS® 
test method 44 chemicals had been used, including the majority of the 20 RCs listed in the PS 
(see 1.3.1, and 2.4 and 4.2 and 6).  
o However, the Rapporteurs also noted at that time that the PS provision not to use 
RCs for test method development and optimisation had not been observed with 
respect to other “me-too's” previously validated, i.e. all other validated RhE methods 
also used the majority of RCs for test method development and optimisation. 
 Second: with respect to the supplementary testing conducted by the two “non-naïve” 
laboratories, the Rapporteurs felt that this was not the appropriate approach (see 1.3.3 and 
1.4 and 4.2 and 10): interpreting the 2011 and 2013 data sets would have been considerably 
easier had the full set of chemicals been re-tested by all laboratories and not only by the 
naïve laboratory.  The relevant PS (see for example OECD STA 220, 2015a) regard post-hoc 
data selection as inappropriate, and the 2013 submission included post-hoc data selection. 
The Rapporteurs considered at that time that a more appropriate, but still imperfect, dataset on 
which to present and judge to the likely true performance of the epiCS® method using the data 
available from this validation study was to combine and analyse the 2013 data from only the naive 
laboratory which re-tested all 20 reference chemicals (believing that this element of the 
supplementary testing did address the most plausible avoidable errors introduced by the initial 
failure to incorporate formal training and proficiency testing and was justified) with the original 2011 
datasets from the other two laboratories (which had re-tested only a carefully selected subset of the 
test chemicals – that is, those responsible for most of the reproducibility errors in the 2011 study).  
Following this approach the performance parameters which the Rapporteurs’ at that time considered 
the most appropriate to judge the performance of the test were as follows (see 10): 
 The re-calculated WLR values produced on this basis were 95%, 84% and 84%. The minimum 
acceptable value in the PS is 90%.  
 However, when considering the figures presented in the 2013 Test Submission including also 
the new data from the non-naïve laboratories, were 95%, 100% and 95%, tending to confirm 
that with experience and full compliance with the SOP acceptable WLR values can be 
obtained.  
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TABLE 2: WLR VALUES (PS target: WLR ≥ 90% concordant predictions) 
LABORATORY 2011 
Data 
2013 
Data 
ESAC WG  
Re-calculation 
COMMENT 
ACS (NAIVE) 74% 95% 95% Re-calculation tended to confirm that poor 
proficiency contributed to the poor WLR values in 
the 2011 report. Another confounding aspect may 
have been cross contamination during the post-
treatment incubation step. 
HCCR 84% 100% 84% Re-calculation tended to confirm that even 
experienced laboratories may require training and 
proficiency testing to transfer the protocol. Another 
confounding aspect may have been cross 
contamination during the post-treatment 
incubation step. 
IIVS 84% 95% 84% Re-calculation tended to confirm that even 
experienced laboratories may require training and 
proficiency testing to transfer the protocol. Another 
confounding aspect may have been cross 
contamination during the post-treatment 
incubation step. Moreover, it is plausible that 
shipment issues may have negatively impacted on 
the tissue quality of the 2011 study. 
 
 The re-calculated Between Laboratory Reproducibility (BLR) value was 88% (with consistent 
predictions for 15 chemicals out of 17 chemicals with valid predictions in all three 
laboratories). The minimum acceptable value in the PS is 80%. The equivalent figure in the 
2013 Test Submission (considering all adjunct testing) was 95%. 
 
TABLE 3: BLR VALUES (PS target: BLR ≥ 80% concordant predictions) 
2011 
Data 
2013 
Data 
ESAC WG  
Re-calculation 
COMMENT 
78% 95% 88% Tended to confirm the need for training and proficiency testing in 
laboratories that wish to establish the test method. 
 
 With respect to Accuracy, the values re-calculated by the Rapporteurs were: Sensitivity 95%, 
Specificity 79%, and overall Accuracy 87%. These values satisfied the acceptance values set 
out in the Performance Standards (80%, 70%, and 75%). 
 
2014 
In 2014 the Rapporteurs reasoned that the ESAC Opinion and EURL ECVAM decision must be based 
on what can be inferred about the values that may have been achieved had the original study design 
not been compromised by a failure to implement and transfer/training/proficiency phase (see 1.3.2), 
and had the full set of test chemicals been re-tested by all three laboratories after the potential 
proficiency issues been resolved. However, the basis of the calculations in the 2013 submission may 
have introduced elements of bias over-estimating the performance of the test method (see above 
and 1.3.3 and 1.4 and 10). 
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The Rapporteurs’ findings informed the resulting ESAC Opinion 2014-01 of 17 November 2014:  
“Recommendations 
At its 40th plenary meeting in October 2014, ESAC discussed the study design and data sets 
submitted in 2011 and in 2013 and concluded that Performance Standard acceptable values 
for BLR, Specificity, Sensitivity and Overall Accuracy were met in the validation study. 
However, only the naïve laboratory satisfied the performance values relating WLR when re-
testing all 20 reference chemicals in 2013. The two other laboratories only met performance 
values when mixing data from the 2011 testing with data from the re-testing in 2013, 
generated under different testing conditions. ESAC is of the opinion that mixing of data from 
2011 and 2013 may introduce sources of bias into the data set submitted to EURL ECVAM in 
2013. Therefore values for WLR for these two laboratories can only be derived from the 2011 
data set and are considered to be below the acceptance threshold, although evaluation of all 
data together tends to support that performance values for WLR can be attained. For the 
final evaluation of the WLR, ESAC recommends to re-test also the remaining 13 and 14 
chemicals so that, ultimately, the full set of chemicals is available also from laboratory 2 and 
laboratory 3 in view of assessing the final WLR values and judging whether these meet the 
Performance Standard acceptable value of 90%. 
ESAC also suggested amendments to  the SOP to stress:  
(1) the importance of an accurate rinsing procedure;  
(2) to improve the description of the washing procedure in the SOP;   
(3) that tissues treated with different test chemicals should not be placed next to each 
 other neither during exposure nor during post-incubation.” 
 
 
2015 
In October 2015, in response to ESAC Opinion 2014-01, the manufacturer submitted a Report3 to 
EURL ECVAM claiming compliance with ESAC’s 2014 recommendations with respect to the need for 
additional test data providing new data for the 13 and 14 chemicals that had not been re-tested 
respectively by HCCR and IIVS in the second validation trial conducted in 2013 (Table 4).  
That Report stated that the two laboratories had also undergone another round of training and 
proficiency testing before generating the additional data. For this they used 5 chemicals from the 
OECD PS table of Proficiency Substances: however, all 5 of these chemicals were also on the list of 
RCs the laboratories then re-tested. In the view of the Rapporteurs a different set of chemicals 
should have been used for training and proficiency testing in this case (see 1.1.4, see 2.4 and 6).  
                                                 
3
 “Report on epiCS® Skin Irritation Test method Validation Study - final testing and submission”, date: October 
29, 2015. Author: Dr Oliver Engelking, Cell Systems Biotechnologie Vertrieb GmbH, Troisdorf, Germany. 
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TABLE 4: Different phases of the PS-based validation of the epiCS® SIT resulting in all three 
laboratories re-testing all chemicals after training and proficiency testing – as reported by 
the test method developer 
ACS HCCR IIVS 
2011 
20 chemicals 20 chemicals 20 chemicals 
2013 + 2015 
2013 2013 2013 
20 chemicals re-tested 
7 chemicals re-tested 6 chemicals re-tested 
2015 2015 
 13 chemicals re-tested  14 chemicals re-tested 
 
The results reported in the 2015 submission with the pooled dataset from the studies of 2013 and 
2015 as recommended by ESAC (with all 20 chemicals tested in all three laboratories after training 
and proficiency testing) can be summarised as: 
 Occurrence of non-qualified tests/runs:  
o If values for the positive or negative controls were outside of the accepted ranges 
(ViabilityPC ≤ 20 %; 1.0 ≤ ODNC ≤ 2.8) the run was considered not qualified and, 
consequently, all tests included within that run were also considered not qualified.  
o As per the PS the mean of triplicate values of each control and test was calculated 
and if the SD was > 18 %, the run and/or test was considered not qualified.  
o Thirty four out of the 212 (16 %) tests conducted in 2013 + 2015 were non-qualified. 
Of these 34 non-qualified tests, 16 occurred due to failure of the positive control 
rather than the SD of the test being > 18 %.  
o The incidence of non-qualified tests is similar to what was observed in the original 
study of 2011 (18 % non-qualified tests).  
o The study acceptance criteria as stipulated in the PS with respect to these elements 
of the validation study were reported as having been met. 
 Complete run sequences:  
o The aggregated data from two of the three laboratories were reported as having 
complete run sequences for all 20 chemicals following re-testing (100 %) (but see 
below and 1.3.5 and 1.4 and 10).  
o The third laboratory, the naïve laboratory (ACS), was reported as having complete 
run sequences for 19 out of 20 chemicals (95 %), thus meeting the PS acceptance 
criterion of ≥ 85 % (based on data from 2013).  
 The incomplete run sequence was obtained for 1-methyl-3-phenyl-1-
piperazine; ACS was unable to generate three qualified runs after the PS 
permitted maximum of 5 independent runs.  
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o The 2013 manufacturer’s report did not reference incomplete run sequences at the 
other two laboratories. 
o In the 2015 test manufacturer’s Report to EURL ECVAM 98.3 % of the run sequences 
were reported as complete, seeming to satisfy the acceptance criterion of ≥ 90 % 
(but see below and 1.3.5 and 1.4 and 4.2 and 10). 
 The reported WLR of 94.7 % at ACS, 100 % at HCCR and 90 % at IIVS meets the acceptance 
criterion of ≥ 90 % (but see below and 1.3.5 and 1.4 and 4.2 and 10). 
 The reported BLR of 84.2 % (based on results from 19 RCs) meets the acceptance criterion of 
≥ 80 % (but see below and 1.3.5 and 1.4 and 4.2 and 10).  
o The PS (OECD 2015a) requires that only chemicals with three complete test run 
sequences are used for the BLR calculation.  
o Since the reference chemical 1-methyl-3-phenyl-1-piperazine did not have complete 
run sequences in all laboratories, it was excluded by the manufacturer for the 
calculation of BLR.  
 The Rapporteurs note that a qualified false negative result and a qualified 
true positive result were obtained for this chemical at HCCR and IIVS, 
respectively. Therefore, the chemical did not show reproducible results 
between laboratories notwithstanding of the incomplete run sequence 
obtained by ACS. If this chemical had been considered in the calculation of 
BLR, the value obtained would be 80 %. 
o The 2015 manufacturer’s report did not reference incomplete run sequences for any 
chemical at the other two laboratories (but see below and 1.3.5 and 1.4 and 4.2 and 
10).  
 The reported Sensitivity of 86.2 % (100 % at ACS, 90 % at HCCR, 70 % at IIVS) meets the 
acceptance criterion of ≥ 80 % (but see below and 1.3.5 and 1.4 and 4.2 and 10). 
 False negative results (based on the mean viability of the three qualified runs) as reported 
were: 
o For 1-methyl-3-phenyl-1-piperazine at HCCR.  
o For 1-methyl-3-phenyl-1-piperazine ACS produced 1 qualified true positive result and 
3 non-qualified false negative results, with the mean of the four runs also being false 
negative.  
o For 1-bromohexane, 1-decanol and di-n-propyl disulphide at IIVS. 
The manufacturer stated the acceptance criteria for false negative results specified in the PS 
are met. 
 The reported specificity of 80 % (80 % in all participating laboratories) meets the PS 
acceptance criterion of ≥ 70 % (but see below and 1.3.5 and 1.4 and 4.2 and 10). 
 False positive results (based on the mean viability of the three qualified runs) were reported 
for allyl-phenoxy-acetate and cinnamaldehyde in all three participating laboratories. The 
manufacturer claimed this satisfies the provisions of the PS. 
 On the basis of the reported overall accuracy of 83.1 % (89.5 % at ACS, 85 % at HCCR, 75 % at 
IIVS) the manufacturer claims this meets the acceptance criterion of ≥ 75 % (but see below 
and 1.3.5 and 1.4 and 4.2 and 10). 
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2016 
In reviewing the 2015 Report submitted by the test developer to EURL ECVAM and all the other 
available documentation and test data, the Rapporteurs noted a significant deviation from the PS 
with respect to the maximum permissible number of re-tests not set out in the 2015 test developer 
Report to EURL ECVAM (see 1.3.5): some non-qualified runs had been not tabulated in the EURL 
ECVAM template, and had not been taken into account when the performance indices provided in 
the 2015 manufacturer’s Report to EURL ECVAM were calculated (see 1.3.5 and 1.4 and 4.1 and 4.2 
and 10).  
o The PS specify that "to complement missing data, a maximum of two additional 
runs… ("re-testing")... may be conducted for each Reference Chemical in each 
laboratory. Non-qualified tests should be documented and reported" (OECD 2015a).  
o This means that each laboratory must not test the same reference chemical more 
than five times, and all non-qualified tests must be taken into account.  
o The PS make no provision for disregarding or discounting test runs known to be non-
qualifying due to technical reasons. 
o However reviewing the raw data for the supplementary testing conducted at IIVS the 
Rapporteurs noted 7 test runs were required to produce three qualifying test runs 
for 1-decanol; and 6 test runs were required to produce three qualifying test runs for  
potassium hydroxide (5% aq).  
o Some of these extra runs (documented in the full data-set) were not reported in the 
EURL ECVAM reporting template as “not qualified”. 
o  Within IIVS “Trial 2” tests were non-qualifying due to failure of the PC, and in “Trial 
5” there were reported problems with bacterial/fungal contamination and failure of 
the positive control.  
o A true positive result (with SD < 18 %) was nevertheless obtained for 1-decanol in 
“Trial 2”. If this result had been accepted, this chemical would have produced non-
concordant results within IIVS, thus lowering the laboratory's WLR to 85 % (PS 
acceptance criterion of ≥ 90 %). 
 
The Rapporteurs are therefore not prepared to rely on the analysis and indices provided in the 
2015 manufacturer’s Report to EURL ECVAM to offer an opinion about the true performance of the 
test method when measured against the PS (see 10). 
The Rapporteurs believe that in order to judge the test method performance against the PS then: 
 Both chemicals (1-decanol and potassium hydroxide (5% aq)) which were re-tested at IIVS 
using more test runs than the PS permits to produce complete run sequences must be 
considered to have failed to produced three qualified run sequences at this laboratory.  
 The BLR must therefore be re-calculated on the basis of the 17 chemicals for which there are 
complete run sequences in all three laboratories. 
 The WLR, Predictive Capacity and other PS required performance figures must also be re-
calculated on this basis. 
When that it is done the results which the Rapporteurs believe should be used to judge the 
performance of the test method are shown in Table 1 (see Executive Summary). 
With the exception of the WLR in one laboratory (88.89%, marginally short of the PS required 
minimum value of >= 90%) all of the PS criteria are met. 
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Whilst one of the relevant Performance Standards makes provision for deviations from the 
acceptance criteria4 - the other does not. 
 
 
                                                 
4
 For example, the 2009 ECVAM Performance Standard (page 5) states “...it is conceivable that deviations from 
these standards may be justified be scientific reasons...”. The OECD Performance Standard does not contain 
this provision. 
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1. Study objective and design 
In requesting advice from ESAC in 2014, EURL ECVAM advised that the Test Submissions for the 
validation study (an initial formal Test Submission in 2011 which was not put forward to ESAC peer 
review, and a revised Test Submission in 2013 following trouble-shooting, supplementary testing and 
data analysis) had been designed and conducted with the specific objective of assessing whether the 
data generated in support of the reproducibility and relevance of the epiCS® test to determine the 
skin irritation potential of chemicals satisfied the requirements of the relevant PS in terms of 
Reproducibility within and between laboratories and with respect to Accuracy of predictions 
(Sensitivity, Specificity, and Overall Accuracy). 
In the subsequent 2016 revised request for advice ESAC was asked to take account of the 2015 
Report from the test method developer and the then current PS. 
 
1.1 Analysis of the clarity of the study objective's definition 
(a) Rapporteurs summary of the study objective as outlined in the Test Submission 
The documentation is clear that the study objective (c.f. Test Plan epiCS SIT, version 2011 and version 
2013, and 2015 Report from the test developer) was to show that the in vitro RhE epiCS® test 
method (initially trademarked and evaluated as EST-1000) satisfactorily discriminates between non-
classified ("no category") and classified ("category 1" or "category 2") chemicals for skin 
corrosion/irritation according to the United Nations Globally Harmonized System of Classification and 
Labelling of Chemicals (UN GHS. UN, 2015). The test method is not intended to differentiate between 
category 1 (skin corrosion) and category 2 (skin irritation). 
To realise this objective, a PS-based ("catch-up") validation study based on the relevant PS (ECVAM 
2009 Performance Standards for in vitro skin irritation test methods based on Reconstructed human 
Epidermis (RhE), and the Performance Standards in Annex 2 of OECD TG 439 (OECD, 2013) now 
published separately in the OECD Series on Testing and Assessment (OECD, 2015a)) was planned and 
conducted involving three laboratories using coded chemicals for blind testing followed by 
independent statistical analysis by statisticians of the federal Institute for Risk Assessment (BfR, 
Germany) in case of the 2011 study and, in case of the adjunct 2013 study, a statistical consultant 
(SHE consulting, Paderborn, Germany). Supplementary test data and analysis are set out in the 2015 
Report from the test developer. 
 
(b) Appraisal of clarity of study objective as outlined in the Test Submission 
The study objectives are sufficiently clear: however, the wording indicates that the objectives relate 
not to determining whether the test method has these properties, but to seeking confirmation that it 
does. 
 
1.2 Quality of the background provided concerning the purpose of the test method  
A PS-based “catch-up” validation study was conducted with the implied purpose of determining 
whether the epiCS® test method is considered suitable for regulatory use in the same context as the 
RhE VRMs from which the PS were derived. 
(a) Analysis of the scientific rationale provided in the Test Submission. 
Scientific rationale is provided in the 2011 and 2013 Test Submissions to EURL ECVAM. These clearly 
describe the biological and mechanistic relevance on the epiCS® test method (known as EST-1000 at 
the time of the 2011 Test Submission) in terms which seek to establish that it meets the essential test 
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method requirements set out in the EURL ECVAM Performance Standard (2009) and the OECD TG 
439 (20135) relating to RhE models for assessing skin irritation potential. 
In 2009 EURL ECVAM (then ECVAM) accepted that the test method satisfied the relevant essential 
test method requirements of the then current PS and that it hence qualified for a PS-based validation 
study using, as a minimum, a pre-defined set of 20 RCs to assess test performance and WLR, BLR and 
predictive capacity. 
(b) Analysis of the regulatory rationale provided in the Test Submission 
This information can be derived from the study documents and the PS referenced in the study 
documents, and are consistent with the provisions of the PS and testing requirements. 
 
1.3 Appraisal of the appropriateness of the study design 
The PS provide the general framework for study design and data analysis. However there are a 
number of problems with the way this programme of work was planned, conducted, analysed and 
reported that complicated the Rapporteurs’ attempts to determine the true test method 
performance in line with the PS provisions and requirements. 
In the view of the Rapporteurs the most serious shortcomings with the study design in relation to the 
provisions of the Performance Standards are:  
1. The selection of RCs for the validation study does not reflect best practice with respect to 
the provisions of the PS. The 20 RCs used for the study are the minimum base-set as 
specified in the PS (EURL ECVAM, 2009; OECD, 2015a). As such they are considered suitably 
representative and balanced with respect to different chemical classes and physical states, 
and skin irritation potential as determined by the best available reference data. However, the 
PS recommend that chemicals used to develop and optimise test methods should not then 
be used for validating the test methods; and make provision for the use of other chemicals in 
their place. In this case the majority of the OECD listed RCs had been used to develop and 
optimise the test method.  See also 2.4. 
a. However, the Rapporteurs are aware that this deviation from the provisions of the 
PS is also a feature of all of the validation studies for other “me too” methods of this 
class that are now included in TG 439 (see for example Tornier et al., 2010). 
2. No training/transfer and proficiency phase was included in the initial ring-trial - with poor 
proficiency then seeming to be a plausible explanation for the variability seen in the 2011 
dataset. The Rapporteurs are concerned that this failure to incorporate formal transfer, 
training and proficiency testing phases within the ring-trial which formed the basis of the 
2011 Test Submission set the scene for further problems as steps were then taken to 
generate a data set permitting a better evaluation of the true performance of the test 
method by proficient laboratories 
3. As a result of selective re-testing and selective data-substitution the test data and analysis 
in the 2013 submission to EURL ECVAM may have introduced sources of “optimism bias” 
with respect to the potential performance of the test method. In 2014 the Rapporteurs felt 
that the selective supplementary testing and statistical analysis which are incorporated in the 
2013 Test Submission, may have introduced sources of bias which, when taken together with 
the concerns about the choice of RCs, made it impossible at that time to properly to 
determine the most relevant, representative and reliable values to use to judge the 
reproducibility and reliability of the test method. 
                                                 
5
 Now superseded by 2015 editions (OECD, 2015a), which do not change the essential test method 
requirements or the minimum required performance values. 
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4. Between 2013 and 2014 the two laboratories which were to do the supplementary testing 
underwent additional training and proficiency testing using 5 of the chemicals which they 
then went on to re-test to provide data for the 2015 test method manufacturer’s Report to 
EURL ECVAM: the supplementary training and proficiency testing should not have used any 
of the chemicals which were to be re-tested.  
5. Data generated to produce the 2015 manufacturer’s Report to EURL ECVAM (but not 
included or used for data analysis within that Report) breached the PS’ provisions with 
respect to permissible re-testing to produce qualified test runs: some of the new data was 
excluded from the completed EURL ECVAM reporting template, and from the test 
manufacturer’s data analysis and conclusions about test method performance. This has 
necessitated the Rapporteurs commissioning additional data analysis in an attempt to 
produce a data-set that that does comply with the re-testing provisions of the PS.   
The inclusion of a naïve test laboratories is in line with the provisions of the PS. Using the PS as the 
benchmark, the Rapporteurs can confirm that the number of participating laboratories, the number 
of RCs, the use of PCs and NCs, and the criteria for test run acceptance meet the requirements for a 
PS-based “catch-up” validation study of this nature. 
 
1.4 Appropriateness of the statistical evaluation 
The 2011 validation study meets the provisions of the Performance Standards with respect to 
statistical power, number of test runs and replicates, and, subject to the comments immediately 
below, the computational rules followed to calculate reproducibility and reliability as reported. 
As Rapporteurs we have concerns regarding: 
 The nature of the selective supplementary testing undertaken after consideration of the 
2011 Test Submission data, and the way that data was then selectively substituted for 
the original 2011 test data in the 2013 submission to EURL ECVAM: both may have 
introduced sources of bias which must be borne in mind when evaluating the 
reproducibility and reliability values, and other test performance indices, reported in the 
2013 Test Submission. 
 The exclusion of some non-qualified test runs from the 2015 manufacturer’s report to 
EURL ECVAM, and the manufacturer’s failure to take account of these in the data analysis.  
In forming a reasoned opinion on the true test method performance, the Rapporteurs commissioned 
additional data analysis to correct for this last shortcoming. 
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2. Collection of existing data 
2.1 Existing data used as reference data 
This epiCS® validation study was conducted using the PS listed 20 RCs. The study documents provide 
no additional reference data. 
 
2.2 Existing data used as testing data 
This epiCS® validation study was conducted using the 20 RCs listed in the relevant PS, and attempted 
to satisfy the provisions of the PS with respect to the minimum acceptable values for reproducibility 
and reliability.  
The study documents provide no additional reference data. 
 
2.3 Search strategy for retrieving existing data 
No systematic search strategy is set out in the documents supplied by the test kit manufacturer. 
 
2.4 Selection criteria applied to existing data 
The test developer had the option of adjusting the test chemical set to take account of the chemicals 
previously used to develop and optimise the test method by substituting or including additional 
chemicals, but did not do so. This decision is not discussed, explained, or justified in the study 
documents.  
For the supplementary training and proficiency test at the two laboratories which provided the 
additional data for the 2015 manufacturer’s Report to EURL ECVAM the test developer had the 
option of using a chemical set which did not contain any of the chemicals which were to be re-tested, 
but did not do so. This decision is not discussed, explained, or justified in the study documents. 
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3. Quality aspects relating to data generated during the study 
3.1 Quality assurance systems used when generating the data 
The manufacture of the epiCS® test kit is undertaken according to defined quality assurance 
procedures, and Lot Release Quality Control and Certification confirm essential morphological and 
functional properties before test kits are issued for use by the manufacturer. 
The 2015 manufacturer’s Report to EURL ECVAM records that one non-qualifying test run at IIVS was 
due to bacterial/fungal infection: the study documents do not provide any insights as to whether this 
was a problem with the test kit as supplied by the manufacturer, or contamination at the test 
laboratory. The study documents also do not specify in which tissues the contamination occurred, i.e. 
the NC treated tissues, the PC treated tissues and/or the test chemical treated tissues. 
Three laboratories conducting the testing summarised in the manufacturer’s submissions undertook 
the studies “in the spirit of GLP”, but had not been required to demonstrate proficiency with the test 
method before the initial ring-trial got underway. 
The 2015 manufacturer’s Report to EURL ECVAM mis-coded some non-qualified test runs due to 
possible technical issues as “not valid” rather than non-qualified. 
 
3.2 Quality check of the generated data prior to analysis 
This validation study was undertaken and co-ordinated by the test manufacturer: it was not initiated, 
owned or managed by EURL ECVAM.  
No records have been provided relating to internal or external audit of the documentation and data 
generated during the study undertaken at the test laboratories. The study documentation available 
to the Rapporteurs does not clearly set out the quality systems used by the manufacturer and/or 
statisticians to verify, collate and quality assure the data supplied by the three laboratories. 
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4. Quality of data used for the purpose of the study (existing and
newly generated) 
4.1 Overall quality of the evaluated testing data (newly generated or existing) 
The Rapporteurs believe that although the laboratories which undertook the testing attempted to 
follow the SOP to the best of their abilities, there were initial proficiency issues; problems with 
compliance with the SOPs; and problems with the way re-testing was finessed in the analysis, 
calculations and conclusions included in the 2015 manufacturer’s Report to EURL ECVAM. 
Supplementary information obtained from the test developer in September 2014 sets out a number 
of potential deviations from the SOPs known or suspected to have taken place at the test 
laboratories when the data was generated for the 2011 submission. These include: 
 test-kit transport issues;
 differences in the way the test chemicals were stored, handled, and applied to the air-tissue
interface;
 issues with the way the chemicals were placed on the test-plates; and
 differences and difficulties with the procedures used to fully remove the test material from
the air-tissue interface after the required exposure time.
These insights were not fully disclosed in the 2013 submission to EURL ECVAM, but were used by the 
test developer to trouble-shoot possible proficiency issues impacting on the reproducibility of the 
test method, and reinforce to the test laboratories how these crucial protocol steps must be 
performed. The manufacturer did not consider that the SOP needed to be revised – merely that the 
laboratories follow best practice and fully comply with the provisions of the SOP. 
In addition, the decision that two of the test laboratories would only re-test the more challenging 
test materials has made it more difficult to determine the likely performance of the test method in 
fully trained and competent laboratories. 
Mention is made elsewhere in this report on the selection of the chemical set for supplementary 
training and proficiency testing at the two laboratories generating additional data for the 2015 
Report to EURL ECVAM. 
Whilst there is arguably a case for judgements of test method performance to exclude non-qualified 
test runs which are known to have been due to technical problems, the PS currently make no 
provision for this. This is something which may merit consideration when the PS are next revised. 
4.2 Quality of the reference data for evaluating reliability and relevance6 
The relevant PS (EURL ECVAM, 2009; OECD, 2015a) contain provisions to the effect that the 
chemicals used to develop and optimise a test method should not then be used in a validation study 
to assess the reproducibility or accuracy of the test method. In this and other cases, contrary to the 
provisions of the PS, the majority of the 20 reference chemicals were used for test method 
development/optimisation and for validation. This is not discussed in the 2011 or 2013 submissions 
to EURL ECVAM. However, the Rapporteurs note that for other RhE “me-too” test methods of the 
6
 OECD guidance document No. 34 on validation defines relevance as follows: "Description of relationship of the 
test to the effect of interest and whether it is meaningful and useful for a particular purpose. It is the extent to 
which the test correctly measures or predicts the biological effect of interest. Relevance incorporates 
consideration of accuracy (concordance) of a test method." 
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same class which are now included in TG 439 this provision has not been satisfied either. This is 
something that might merit consideration when the PS are next revised. 
Although the studies which generated the 2011 and 2013 Test Submissions, and the 2015 
manufacturer’s Report to EURL ECVAM, were reported to have been undertaken in compliance with 
the agreed protocol, the findings support the conclusion that at the time the data for the 2011 Test 
Submission was generated, the laboratories, and in particular the naïve laboratory, were not fully 
proficient. This tends to be confirmed (see above) by supplementary information disclosed by the 
test method developer in September 2014: there were substantial differences and difficulties with a 
number of crucial protocol steps when the study to generate the data used in the 2011 submission 
was undertaken, primarily, but not exclusively, at the naïve laboratory. The test developer used this 
information to identify key differences and difficulties, and sought to ensure these were remedied 
before the supplementary testing was performed.  
After remedial action had been taken to improve proficiency and SOP compliance, supplementary 
testing of the full set of PS RCs (n=20) at the naïve laboratory improved the reported reproducibility 
which met the target value as outlined in the PS.  
On that basis the Rapporteurs are satisfied that a plausible partial explanation for the poor 
reproducibility in the 2011 ring trial was the poor proficiency.   
The Rapporteurs also considered whether the 2011 and 2013 test data provided grounds for it being 
plausible that the poor reproducibility reported in 2011 was instead the result of high intrinsic 
variability of the test-kits. However, had that been the case the measures to improve proficiency 
should not of themselves have changed the re-testing results and the problems with reproducibility 
would not have been restricted to the same subset of test chemicals in all three laboratories. 
The Rapporteurs also have concerns about the other elements of the design of the supplementary 
testing which was performed following the poor reproducibility of the test method report in the 2011 
ring trial, and the way the datasets were used to derive the reliability of the performance figures 
submitted in support of the Test Submission received by EURL ECVAM from the test developer in 
2013.  
In summary, in 2013 the naïve laboratory, after formal training and proficiency testing, re-tested the 
original 20 RCs. The other two laboratories re-tested the six chemicals responsible for most of the 
reproducibility errors observed, and a seventh chemical in one of the laboratories only because it 
generated invalid run sequences during the 2011 ring-trial. The results of the supplementary testing 
undertaken by all three laboratories were then substituted for the results obtained for the same 
chemicals in the same laboratories as reported in the 2011 submission to EURL ECVAM, and it is on 
that basis revised Reproducibility and Accuracy figures were calculated and supplied to EURL ECVAM 
by the test developer in 2013.  
The selective re-testing and the substitution of data seem to violate the PS’ provisions with respect 
to selective re-testing and data selection. As such in 2014 the Rapporteurs  believed the data 
generated in the second round of testing should be used to support the 2011 submission in view of 
considering whether the problems encountered had been convincingly resolved on the basis of the 
hypotheses offered and the measures taken. However the data should not be used to selectively 
replace previous data.  
The Rapporteurs accept the 2013 Test Submission data as tending to confirm that the origin of the 
reproducibility problems in the 2011 submission was the imperfect proficiency and competency of 
the laboratories, and that it also provides useful insights into need for training and proficiency testing 
being required to ensure laboratories can competent perform the test. 
However, the Rapporteurs were not convinced that the reported Reproducibility of the epiCS® test 
method as set out in the 2013 Test Submission constitute the most relevant, representative or 
reliable dataset to use to interpret the findings of this study.  
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The Rapporteurs believe two features of the 2013 study design represent potential sources of 
optimism-bias, each of which has the potential to inflate the calculated Reproducibility and Accuracy 
values. 
 First: the PS state that for validation studies, chemicals used to develop and optimise the test 
method should not then be used for the validation study. In this case the 20 RCs used for the 
study are those recommended in the PS (EURL ECVAM, 2009; OECD, 2015a), and the majority 
of these chemicals had also been used to develop and optimise the epiCS® test method.  
o However, the Rapporteurs are aware that this provision was not observed by other 
validation studies of “me-too” methods of the same class that have been validated 
and accepted for regulatory use. 
 Second: with respect to the supplementary testing conducted by the two “non-naïve” 
laboratories, the Rapporteurs feel that this was not the best approach: interpreting the 2011 
and 2013 data sets would have been considerably easier had the full set of chemicals been 
re-tested by all laboratories and not only by the naïve laboratory.  
In 2014 the Rapporteurs advised that at that time a more appropriate, but still imperfect, dataset on 
which to present and judge to the likely performance of the epiCS® method using the data available 
from this validation study is to combine and analyse the 2013 data from only the naïve laboratory (as 
we believe this element of the supplementary testing did address the most plausible avoidable errors 
introduced by the initial failure to incorporate formal training and proficiency testing and was 
justified) with the original 2011 datasets from the other two laboratories. On the basis of this re-
calculation by the Rapporteurs the only values which fall short of the minimum acceptable value 
(90%) set out in the PS are the WLR values produced for two of the three laboratories (84% and 
84%).  
Following this approach the performance parameters were as follows (see Table 2, above): 
 The re-calculated WLR values produced on this basis were 95%, 84% and 84%. The minimum 
acceptable value in the Performance Standards is 90%.  
 However, when including also the supplementary data (2013) from the non-naïve 
laboratories the values were 95%, 100% and 95%, tending to confirm that with experience 
and full compliance with the SOP acceptable WLR values can be obtained.  
The problems with the data analysis in the 2015 Report by the test developer to EURL ECVAM are 
discussed elsewhere. 
 The re-calculated Between Laboratory Reproducibility (BLR) value was 88% (with consistent 
predictions for 15 chemicals out of 17 chemicals with valid predictions in all three 
laboratories). The minimum acceptable value in the PS is 80%. The equivalent figure in the 
2013 Test Submission was 95% (see Table 3, above). 
 With respect to accuracy, the re-calculated values produced were: Sensitivity 95%, Specificity 
79%, and Overall Accuracy 87%. These values satisfy the acceptance values set out in the 
Performance Standards (80%, 70%, and 75%). It is noted that already the 2011 study met the 
acceptance criteria for predictive capacity. 
The Rapporteurs believe that ESAC Opinions and EURL ECVAM decisions must be based on what can 
be inferred about the values that may have been achieved had the original study design not been 
compromised by a failure to implement and transfer/training/proficiency phase, and had the full set 
of test chemicals been re-tested by all three laboratories after the potential proficiency issues been 
resolved. 
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One of the relevant PS makes provision for minor deviations from the acceptance criteria7 - the other 
does not. In this case it is plausible both that the initial failure to include a transfer, training and 
proficiency phase resulted in a lack of proficiency in performing crucial elements of the SOPs at the 
test laboratories in 2011; and that the 2013 test data, generated after remedial action had been 
taken, tends to support the hypothesis that subject to attaining proficiency appropriate 
reproducibility can be attained.  
On that basis the Rapporteurs accept that it is plausible the minimum Performance Standards 
acceptable values for WLR, BLR, Specificity, Sensitivity and Overall Accuracy can be met by trained 
and competent laboratories – and that formal training and proficiency testing should be required. 
The 2015 manufacturer’s Report to EURL ECVAM supplied additional test data in line with the 2014 
ESAC Opinion. The Rapporteurs have concerns about the quality of the data and analysis set out in 
the 2015 manufacturer’s report to EURL ECVAM: at IIVS more than 5 test runs were required to 
produce a completed test run sequence for two of the chemicals tested. However, the PS allow a 
maximum of 5 test runs. Only 5 test runs for each of these chemicals were tabulated in the EURL 
ECVAM reporting template claiming that three complete test run sequences had been obtained – the 
test method developer claimed these to be completed test run sequences, and produced test 
method performance data based on that assumption. 
The additional non-qualified test runs ("trials" 2 and 5 at IIVS) were not reported on the EURL ECVAM 
template, and were not taken into account when the performance figures were calculated by the test 
developer. One or both of these two additional test runs may have failed due to technical problems 
(in one case the failure was due to a PC value outside the required range, and in another 
bacterial/fungal contamination and also a PC value outside the acceptable range). These test runs 
seem to have been disregarded when the performance figures well calculated, having been 
considered to be “non-valid” rather than “non-qualified” test runs. The current PS make no provision 
for making this distinction or treating the results in this way. 
For that reason for their evaluation of test method performance the Rapporteurs commissioned a 
supplementary analysis of the data using a data-set adjusted to comply with the PS re-testing 
provisions. 
 
4.3 Sufficiency of the evaluated data in view of the study objective 
This is discussed fully at 4.2 above. 
 
 
                                                 
7
 For example, the 2009 ECVAM Performance Standard (page 5) states “...it is conceivable that deviations from 
these standards may be justified be scientific reasons...”. The OECD Performance Standard does not contain 
this provision. 
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5. Test definition (Module 1) 
5.1 Quality and completeness of the overall test definition  
All of these are clearly set out in the 2013 Test Submission, and in 2009 was deemed by EURL ECVAM 
(then ECVAM) to satisfy the requirements of the essential test method components of the relevant 
Performance Standards. 
Between the initial ring-trial and the supplementary testing, the Epidermal Skin Test EST-1000, was 
renamed "epiCS® SIT". EURL ECVAM requested and received a formal assurance from the submitter 
that only the name but no other parameter of the test method had been subject to change. 
The Rapporteurs noted that during the validation study the nature of the plastic inserts which form 
part of the test kit were changed, but that this did not compromise test performance values. The 
Rapporteurs consider that the ability of the test method to withstand such a change in 
manufacturing process tends to confirm the robustness of the test method and its external validity. 
 
5.2 Quality and completeness of the documentation concerning SOPs and prediction 
models 
The Rapporteurs are satisfied that the 2013 Test Submission, and supporting reference documents 
including the supplementary information supplied by the test developer in September 2014, are 
sufficiently detailed and complete on these points. The definitive SOP is “INVITTOX Protocol epiCS® 
SKIN IRRITATION TEST Standard Operating Procedure (SOP epiCS SIT) Version 4.0 November 2012”.  
The SOP contains a sub-protocol (Interference Test) invoked for chemicals (strongly coloured and/or 
MTT reducers) which may not otherwise be compatible with or properly categorised by the epiCS® 
test method. The reproducibility and reliability of this sub-protocol were not evaluated during this 
validation study. 
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6. Test materials 
6.1 Sufficiency of the number of evaluated test items in view of the study objective 
The 20 RCs used are the minimum base-set as specified in the PS (EURL ECVAM, 2009; OECD, 2015a). 
As such they are sufficient in number and suitably representative and balanced with respect to 
different chemical classes and physical states, and skin irritation potential as determined by the best 
available reference test methods and reference data. 
The majority of these chemicals has also been used to develop and optimise the epiCS® test method. 
In these circumstances within the PS framework provision is made for their substitution by chemicals 
not used for test method development or optimisation. This option, had it been exercised, would 
have better met the letter and spirit of the Performance Standards. 
 
6.2 Representativeness of the test items with respect to applicability 
The 20 RCs used are as listed in the relevant PS, and are suitably representative and balanced with 
respect to different chemical classes and physical states, and skin irritation potential as determined 
by the best available reference test methods and data. 
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7. Within-laboratory reproducibility (WLR) (Module 2) 
7.1 Assessment of repeatability and reproducibility in the same laboratory 
See Section 4.2 – specifically the final dataset relied upon by the Rapporteurs. 
 
7.2 Conclusion on within-laboratory reproducibility as assessed by the study 
See Section 4.2 – specifically the final dataset relied upon by the Rapporteurs, which shows a re-
calculated value (88.89%) for one laboratory that falls fractionally short of the PS criterion of ≥ 90%. 
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8. Transferability (Module 3) 
8.1 Quality of design and analysis of the transfer phase 
The study which generated the data in support of the 2011 Test Submission did not include a formal 
transferability/training/proficiency testing phase. In the view of the Rapporteurs this was a significant 
omission, and is likely to be the main cause of the 2011 study’s failure to meet the required 
reproducibility targets. 
Remedial action was undertaken prior commencing the supplementary round of re-testing, but full 
details of what was involved were only disclosed by the test method developer in September 2014. 
 
8.2 Conclusion on transferability to a naïve laboratory / naïve laboratories as assessed by 
the study 
The study which generated the data in support of the 2011 Test Submission did not include a formal 
transferability/training/proficiency testing phase. The WLR for the naïve laboratory for that round of 
the validation study was 74%, the values for the non-naïve laboratories were both 84%. 
After remedial action was taken in an attempt to improve proficiency the naïve laboratory re-tested 
the full set of 20 RCs the WLR increased to 95%. This tends to confirm that, subject to suitable 
transfer/training/proficiency testing, the epiCS® method can be successfully transferred to a naïve 
laboratory – and that this should be required of any new laboratory seeking to use the test method. 
The 2011 WLR at the two non-naïve laboratories (84% in each laboratory) was below the minimum 
acceptable PS value of 90%. Values of 95% and 100% were obtained when the 2013 re-testing data 
was substituted for the 2011 data: this suggests that even laboratories experienced and proficient in 
the use of similar test methods require training and proficiency testing if planning to perform the 
epiCS® method. 
In addressing the 2014 ESAC recommendation regarding additional testing, the two non-naïve 
laboratories underwent additional training and proficiency testing using 5 test chemicals, all of which 
were then to be re-tested to generate the required test data for the 2015 test developer Report to 
EURL ECVAM. This is not best practice: none of the chemicals to be tested should have been used for 
this supplementary round of proficiency testing. 
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9. Between-laboratory reproducibility (BLR) (Module 4) 
9.1 Assessment of reproducibility in different laboratories 
See Section 4.2 – specifically the final dataset relied upon by the Rapporteurs. 
 
9.2 Conclusion on between-laboratory reproducibility as assessed by the study 
See Section 4.2 – specifically the final dataset relied upon by the Rapporteurs which estimates BLR at 
88.24% (with a PS target of ≥ 80%). 
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10. Predictive capacity and overall relevance (Module 5)  
10.1 Adequacy of the assessment of the predictive capacity in view of the purpose 
The predictive capacity values were calculated using the computational model provided in the 
relevant PS. 
The predictive capacity figures provided in both the 2011 and the 2013 Test Submissions appeared to 
satisfy the minimum acceptable values for test method Sensitivity, Specificity, and Overall Accuracy. 
However, the Rapporteurs do not believe that the reported reproducibility and accuracy of the 
epiCS® test method as set out in either the 2011 or 2013 Test Submissions are the most relevant and 
reliable datasets to use to interpret the findings of this study with respect to reliability, and have 
concerns about the design of the supplementary testing which was performed following the poor 
reproducibility of the test method report in the 2011 ring trial, and the way the data was then 
substituted for the original ring-trial data. The details of the supplementary testing and data analysis, 
and possible sources of bias, are described above. 
In 2014 the Rapporteurs reasoned that a more relevant and appropriate dataset on which to present 
and judge to the performance of the epiCS® method using the data available from this validation 
study is to combine and analyse the 2013 data from the naïve laboratory (as we believe this element 
of the supplementary testing did address avoidable errors introduced by the initial failure to 
incorporate formal training and proficiency testing and was justified) with the original 2011 datasets 
from the other two laboratories. 
When that is done: 
 
TABLE 6: Predictive Capacity as described in the two submissions (2011 and 2013) and as re-
calculated by the ESAC Rapporteurs and EURL ECVAM. 
 2011 2013 2014 ESAC WG  
re-derived value 
Performance Standard 
Minimum Acceptable Value 
Sensitivity 93% 97% 100%* 80% 
Specificity 78% 80% 79% 70% 
Overall Accuracy 85% 88% 89% 75% 
*) the number is higher than the 2013 values since in 2013 HCCR had reported one FN, which reduces the Sensitivity. When 
not considering the 2013 re-testing data from IIVS and HCCR, but combining the 2011 data from these two labs with the 
2013 re-testing data from ACS (all 20 chemicals), there is no FN in the data matrix.  
 
On that basis the Rapporteurs were satisfied that for all reasonable Predictive Capacity values that 
can be derived meet the minimum acceptable value set out in the PS. 
Based on the 2013 test data only one Category 2 material (1-methyl-3-phenylpipeazine) was 
misclassified as a non-irritant by one laboratory. All three laboratories derived appropriate 
classifications for the Category 2 substances 1-decanol and di-n-propyl disulphide. All laboratories 
misclassified the non-irritants allyl phenoxy acetate and cinnamaldehyde as irritants. 
In a letter of September 2014, the test developer speculated, but provided no evidence, to test 
material oxidation being a possible confounding factor. 
In its 2015 Report to EURL ECVAM in response to the 2014 ESAC Opinion consideration of 
supplementary data and analysis purported to show the PS requirements for Relevance and Accuracy 
has been met: the same is true when the judgement is made on the basis of the revised calculation 
commissioned by the Rapporteurs (see 4.2) 
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TABLE 7: Predictive Capacity as described in the 2015 manufacturer’s Report to EURL ECVAM, and 
the further analysis commissioned by the Rapporteurs. 
 2015 Manufacturer’s 
Report to EURL 
ECVAM 
2015 
Rapporteurs’ re-
worked analysis 
Performance 
Standard Minimum 
Acceptable Value 
Sensitivity 86.21% 88.89% 80% 
Specificity 80.00% 80.00% 70% 
Overall Accuracy 83.05% 84.21% 75% 
 
 
10.2 Overall relevance (biological relevance and accuracy) of the test method in view of 
the purpose 
The Rapporteurs consider that the 2013 Test Submission and the supporting documents confirm the 
biological/mechanistic relevance, and relevance in terms of making accurate measurements and 
predictions for the skin irritation potential endpoints set out in the study objectives: and that the 
general assertions made to this effect in the 2013 Test Submission are substantiated by the data 
generated during the validation study and adjunct testing. 
The Rapporteurs also consider the performance criteria set out in the 2015 manufacturer’s report to 
EURL ECVAM did not give proper consideration to the reporting and analysis of non-qualified test 
runs, and rely instead on a supplementary analysis commissioned to address this problem.  
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11. Applicability domain (Module 6)  
11.1 Appropriateness of study design to conclude on applicability domain, limitations and 
exclusions 
On the basis of the available evidence (as at May 2016) the Rapporteurs conclude that the 
applicability domain of the epiCS® test method can be expected to match that of the validated RhE in 
vitro test methods from which the relevant PS were derived. 
The chemicals which were inappropriately classified in course of the study tend to be those which 
have been problematical with the other validated RhE in vitro test methods. 
 
11.2 Quality of the description of applicability domain, limitations, exclusions 
These are only briefly discussed in the 2013 Test Submission. See 11.1. 
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12. Performance standards (Module 7) 
This section is not applicable to the study.  
12.1 Adequacy of the proposed Essential Test Method Components 
Not applicable – see immediately above. 
12.2 Adequacy of the Reference Chemicals 
Not applicable – see immediately above. 
12.3 Adequacy of proposed performance target values 
Not applicable – see immediately above. 
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13. Readiness for standardised use 
13.1 Assessment of the readiness for regulatory purposes 
The transfer/training/proficiency requirements need to be defined, and made pre-requisites for the 
use of this test method. An SOP for training and transfer should be agreed/developed for this 
purpose. 
The sub-protocol on interference test (to be used with Colour interfering and/or direct MTT reducing 
test chemicals) has yet to be validated.  
 
13.2 Assessment of the readiness for other uses  
The Rapporteurs see no reason in principle why trained and competent laboratories should not use 
this test method for relevant non-regulatory purposes. 
 
13.3 Critical aspects impacting on standardised use 
The Rapporteurs consider training and proficiency testing to be essential requirements, and 
understand that the manufacturer can and will assist with this. In addition an appropriate SOP for 
transferability and proficiency testing is required. 
 
13.4 Gap analysis 
Training and proficiency testing are essential requirements, and the manufacturer can and will assist 
with this. In addition an appropriate SOP for transferability and proficiency testing is required. 
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14. Other considerations 
The Rapporteurs are grateful for the information provided by the test developer, notwithstanding 
the fact that some relevant information was only disclosed on request, and further analysis was 
required to bring the analysis set out in the 2015 manufacturer’s Report to EURL ECVAM into 
compliance with the PS requirements relating to re-testing. 
The quality and completeness of the background material provided, and the presentation of the 
findings, are generally of a good standard.  
There are issues relating to experimental design; and the data reporting, data analysis, and 
conclusions supplied by the manufacturer. These are covered in detail elsewhere in this report. 
Each RC was evaluated in at least three independent runs in each laboratory, with the test runs 
conducted at different time points and using different tissue batches. The precise requirements for 
“independence” of runs are not specified in the Performance Standards: some of the “independent” 
test runs in this validation were separated by short time intervals, and some of the test-kits were 
from consecutive of very close test-kit production runs. The meaning of “independence” might be 
clarified in future PS. 
Arguably in determining test method performance test runs which are currently classed as “non-
qualifying” due to technical reasons (for example PC values outside the required range, or 
bacterial/fungal contamination) might reasonably be set aside as “not valid” rather than included as 
“non-qualifying runs” and consequently originating non-qualified test for all test chemicals included 
in those runs; however, to avoid data-selection this should only be considered if the technical issues 
are identified and the test run aborted before test data on the RCs is collected.  At present the PS 
make no provision for this. This might merit consideration when the PS are next revised. 
There are occasions when failure to produce a complete test run sequence (three qualified test runs) 
for more than one test chemical in one laboratory leads to those chemicals being excluded from the 
WLR and BLR calculations. There may be a case for considering whether in cases where this markedly 
reduces the number of chemicals included in the final analysis, mindful that these may be the more 
challenging test chemicals, that the requirement for three qualified test runs in each laboratory 
might be reduced to one or two for assessing BLR. Before considering whether this should be 
considered when the PS are next revised, some existing datasets might be reworked to determine 
what effect this might have on the calculation of test method performance indices. 
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15. Conclusions on the study 
15.1 ESAC WG summary of the results and conclusions of the study 
See Executive Summary. 
 
15.2 Extent to which study conclusions are justified by the study results alone 
See Executive Summary. 
 
15.3 Extent to which conclusions are plausible in the context of existing information 
See Executive Summary and Section 4.2. 
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16. Recommendations 
16.1 General recommendations 
The Rapporteurs offer the following draft recommendations for consideration: 
1. The epiCS® RhE test method can only be deemed to satisfy the minimum performance 
criteria  (for Reproducibility and Predictive Capacity) requirements set out in the EURL 
ECVAM/OECD Performance Standards for in vitro skin irritation testing using Reconstructed 
human Epidermis (RhE) (EURL ECVAM, 2009; OECD, 2015a), to discriminate between “non-
irritant” (No Category = not-classified) and classified chemicals ("category 1" or "category 2") 
for skin corrosion/irritation, and be “sufficiently similar” to the existing Validated Reference 
Methods, if account is taken of the PS provision that minor deviations (in this case a minor 
shortfall in the estimated WLR value) may be accepted for scientific reasons, and the poor 
reproducibility values reported for the 2011 study were due to poor proficiency on the part 
of the untrained laboratories conducting the tests. 
2. The OECD TG439 (2013 and 2015) has no similar provision, and consideration should be 
given to its being updated to take account of this.  
3. The use of the epiCS® RhE test method for regulatory purposes for skin irritation testing be 
conditional upon all laboratories demonstrating that they have undertaken appropriate 
training and proficiency testing. The test method SOP should be amended to make provision 
for this. This might be considered for other “me-too” RhE test methods. 
4. Recommended to emphasize in SOP: 
a. importance of washing steps; 
b. keeping chemicals separated during exposure and post-incubation 
5. The Rapporteurs believe that any revised PS should contain more explicit provisions and 
advice for how studies should be designed and conducted if any of the chemicals listed as 
Performance Standards Reference Chemicals were also used to develop or optimise the test 
method. 
 
16.2 Specific recommendations (e.g. concerning improvement of SOPs) 
A transfer, training and proficiency SOP is required. 
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